



10/506794  
PCT/GB 2003/000918




INVESTOR IN PEOPLE

## PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ




I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

*Andrew Grange*

Dated 19 March 2003

BEST AVAILABLE COPY



1/77

# Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road  
Newport  
South Wales  
NP10 8QQ

1. Your reference P.84806A GCW

2. Patent application (The) 0222378.2 26 SEP 2002

27SEP02 E751346-1 000192  
P01/7700 0.00-0222378.2

3. Full name, address and postcode of the or of each applicant (underline all surnames) ARROW THERAPEUTICS LIMITED  
Britannia House, 7 Trinity Street  
London SE1 1DA  
United Kingdom

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation

United Kingdom

7708217002

4. Title of the invention TRANSPONON

5. Name of your agent (if you have one) J.A. KEMP & CO.

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

14 South Square  
Gray's Inn  
London  
WC1R 5JJ

Patents ADP number (if you know it)

26001

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country Priority application number (if you know it) Date of filing (day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application Date of filing (day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

- a) any applicant named in part 3 is not an inventor, or
  - b) there is an inventor who is not named as an applicant, or
  - c) any named applicant is a corporate body.
- See note (d))

Yes

## Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form	-
Description	57
Claim(s)	9
Abstract	1
Drawing(s)	7 only

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature

J.A. Kemp & Co.  
J.A. KEMP & CO.

Date 26 September 2002

12. Name and daytime telephone number of person to contact in the United Kingdom

G.C. WOODS  
020 7405 3292

### Warning

*After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.*

### Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.*
- Write your answers in capital letters using black ink or you may type them.*
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.*
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.*
- Once you have filled in the form you must remember to sign and date it.*
- For details of the fee and ways to pay please contact the Patent Office.*

## TRANSPOSON

### Field of the Invention

This invention relates to a new type of transposon. The transposon may be  
5 used in methods for the identification of essential and conditional essential genes, in particular in bacteria.

### Background to The Invention

The increase in prevalence of antibiotic-resistant bacteria, for example, has  
10 renewed interest in the search for new targets for antibacterial agents. Essential genes and in particular the proteins which they encode may be good substrates for use in screens for antibacterials, antiparasitics, fungicides, pesticides and herbicides. Essential genes and their protein products potentially represent such targets.

Additionally, there is an interest in the identification of conditional essential  
15 genes, that is genes which are essential for the survival of an organism in a particular environment. In the case of pathogenic bacteria, for example, conditional essential genes include those which are required for survival in a host. Such genes and the proteins which they encode may also be good targets for use in screens for antibacterials. In particular, bacteria which carry mutations in such genes may be  
20 useful in attenuated live vaccines.

### Summary of The Invention

Essential genes are those genes which, when missing (eg. because of a chromosomal deletion) or mutated to render them non-functional, result in a lethal  
25 phenotype. That is, they are genes without which an organism cannot survive. Conditional essential genes are those genes which, although not absolutely essential for the survival of an organism under all conditions, are essential for survival under various conditional restraints. Examples of particular conditional restraints include survival at elevated temperatures and survival of a pathogen within its host.

30 A number of transposon-based strategies have been developed for the

identification of essential and conditional essential genes. We have now devised a new set of transposons. The transposons can be used in a variety of methods for the identification of essential and conditional essential gene in the genome of an organism.

- 5        According to the invention there is thus provided a transposon which comprises an RNA polymerase recognition site and a homing endonuclease recognition site.

The invention also provides:

- use of a transposon of the invention in a method for the identification of an  
10    essential or a conditional essential gene;
- a method for identifying an essential gene of an organism, which method comprises:
  - (i)     providing a library of transposon insertion mutants of the said  
         organism, wherein the transposon is a transposon of the invention;
  - 15        (ii)    isolating chromosomal DNA from the library of (i);
  - (iii)    digesting the chromosomal DNA with a restriction endonuclease that  
          is capable of cutting 5' to the RNA polymerase recognition site(s) in the transposon  
          and 3' to the RNA polymerase recognition site(s) in the chromosomal DNA flanking  
          the transposon insertion site;
  - 20        (iv)    transcribing the resulting digested DNA from the RNA polymerase  
          recognition site(s) in the said DNA;
  - (v)     hybridising the resulting RNA with an oligonucleotide array; and
  - (vi)    identifying a probe on the oligonucleotide array which corresponds to  
          an essential gene of the organism;
  - 25        -        a method for identifying a conditional essential gene of an organism, which  
          method comprises:
    - (a)     providing a first sample of a library of transposon insertion mutants of  
          the said organism (input library);
    - (b)     providing a second sample of the library and subjecting that sample to  
30    a conditional restraint;

(c) collecting the mutants that survive the conditional restraint in step (ii) to give a second library (output library);

(d) carrying out a method according to steps (ii) to (iv) of the method set out above on the input library from step (a) and on the output library from step (c);

5 (e) hybridising the transcribed RNA derived from the input library and from the output library separately to copies of the same oligonucleotide array or, if the RNA derived from the two libraries is differentially labelled, to the same oligonucleotide array; and

(f) identifying a probe on the oligonucleotide array(s) which corresponds  
10 to a conditional essential gene of the organism;

- a method for identifying an essential gene of an organism, which method comprises:

(i) providing a library of transposon insertion mutants of the said organism, wherein the transposon is a transposon of the invention;

15 (ii) isolating chromosomal DNA from the library of (i);

(iii) digesting the chromosomal DNA with a restriction endonuclease that is capable of cutting 5' to the RNA polymerase recognition site(s) in the transposon and 3' to the RNA polymerase recognition site(s) in the chromosomal DNA flanking the transposon insertion site;

20 (iv) transcribing the resulting digested DNA from the RNA polymerase recognition site(s) in the said DNA;

(v)' reverse transcribing the resulting RNA;

(v)" hybridising the resulting cDNA with an oligonucleotide array; and

(vi) identifying a probe on the oligonucleotide array which corresponds to  
25 an essential gene of the organism;

- a method for identifying a conditional essential gene of an organism, which method comprises:

(a) providing a first sample of a library of transposon insertion mutants of the said organism (input library);

30 (b) providing a second sample of the library and subjecting that sample to

a conditional restraint;

(c) collecting the mutants that survive the conditional restraint in step (ii) to give a second library (output library);

5 (d) carrying out a method according to steps (ii) to (v)' of the method set out above on the input library from step (a) and on the output library from step (c);

(e) hybridising the reverse transcribed cDNA derived from the input library and from the output library separately to copies of the same oligonucleotide array or, if the cDNA derived from the two libraries is differentially labelled, to the same oligonucleotide array; and

10 (f) identifying a probe on the oligonucleotide array(s) which corresponds to a conditional essential gene of the organism;

- use of an essential or conditional essential gene identified by a method as set out above, or a polypeptide encoded by a said gene, in a method for identifying an inhibitor of transcription and/or translation of that gene and/or activity of a

15 polypeptide encoded that gene;

- a method for identifying an inhibitor of transcription and/or translation of an essential or conditional essential gene and/or an inhibitor of activity of a polypeptide encoded by a said gene, which method comprises:

20 (a) identifying an essential or conditional essential gene by a method as set out above; and

(b) determining whether a test substance can inhibit transcription and/or translation of a gene identified in step (a) and/or activity of a polypeptide encoded by a said identified gene, thereby to identify a said inhibitor;

- an inhibitor identified by such a method according to claim;

25 - an inhibitor of the invention for use in a method of treatment of a bacterial, fungal or eukaryotic parasite infection, wherein the essential or conditional essential gene used to identify the inhibitor is a bacterial, fungal or eukaryotic parasite essential or conditional essential gene;

- use of such an inhibitor in the manufacture of a medicament for use in the  
30 treatment of a bacterial, fungal or eukaryotic parasite infection;

- a pharmaceutical composition comprising such an inhibitor and a pharmaceutically acceptable carrier or diluent;
- a method of treating a host suffering from a bacterial, fungal or eukaryotic parasite infection, which method comprises the step of administering to the host a therapeutically effective amount of such an inhibitor;
- a method for the preparation of a pharmaceutical composition, which method comprises:
  - (a) identifying an inhibitor of transcription and/or translation of an essential or conditional essential gene of an organism and/or an inhibitor of activity of a polypeptide encoded by a said gene by a method as set out above wherein the essential or conditional essential gene is a bacterial, fungal or eukaryotic parasite essential or conditional essential gene; and
  - (b) formulating the inhibitor thus identified with a pharmaceutically acceptable carrier or diluent;
- a method for treating a host suffering from a bacterial, fungal or eukaryotic parasite infection, which method comprises:
  - (a) identifying an inhibitor of transcription and/or translation of an essential or conditional essential gene of an organism and/or an inhibitor of activity of a polypeptide encoded by a said gene by a method as set out above wherein the essential or conditional essential gene is a bacterial, fungal or eukaryotic parasite essential or conditional essential gene;
  - (b) formulating the inhibitor thus identified with a pharmaceutically acceptable carrier or diluent; and
  - (c) administering to the host a therapeutically effective amount of an inhibitor thus formulated;
- an inhibitor of the invention, wherein the essential or conditional essential gene is a plant bacterial, plant fungal or plant pest essential or conditional essential gene;
- use of such an inhibitor as a plant bactericide, fungicide or pesticide;
- an inhibitor of the invention, wherein essential or conditional essential gene is



a plant essential or conditional essential gene;

- use of such an inhibitor as a herbicide;

- a bacterium attenuated by a non-reverting mutation in one or more genes identified by a method of the invention;

5 - a vaccine comprising such a bacterium and a pharmaceutically acceptable carrier or diluent;

- a bacterium as described above for use in a method of vaccinating a human or animal;

- use of such a bacterium for the manufacture of a medicament for vaccinating  
10 a human or animal;

- a method for raising an immune response in a mammalian host, which method comprises the step of administering to the host a bacterium as set out above;

- a method for preparing an attenuated bacterium, which method comprises:

(a) identifying a conditional essential gene in a bacterium by a method of  
15 the invention; and

(b) introducing a non-reverting mutation into a thus-identified conditional essential gene of the bacterium, thereby to attenuate the bacterium;

- a method for the preparation of a vaccine, which method comprises:

(a) identifying a conditional essential gene in a bacterium by a method of  
20 the invention;

(b) introducing a non-reverting mutation into a thus-identified conditional essential gene of the bacterium, thereby to attenuate the bacterium; and

(c) formulating the attenuated bacterium with a pharmaceutically acceptable carrier or diluent; and

25 - a method for raising an immune response in a mammalian host, which method comprises:

(a) identifying a conditional essential gene in a bacterium by a method of the invention;

(b) introducing a non-reverting mutation into a thus-identified conditional  
30 essential gene of the bacterium, thereby to attenuate the bacterium;

- (c) formulating the attenuated bacterium with a pharmaceutically acceptable carrier or diluent; and
- (d) administering to the host the attenuated bacterium thus formulated.

## 5 **Brief Description of The Figures**

Figure 1 shows a diagrammatic representation of the "Gene Kelly" transposon consisting of ME (mosaic end IS sequences), binding sites for the SP6 and T7 RNA polymerases, homing endonuclease sites for I-*SceI* and PI-*PspI*, an R6k origin of replication and a kanamycin resistance cassette.

10 Figure 2 sets out the sequence of the "Gene Kelly" transposon.

Figure 3 shows a diagrammatic representation of the original epicentre EZ:Tn R6k ori Kan transposon with the oligonucleotide sequences overlaid. Black boxes represent matching sequence between PCR oligonucleotides and the epicentre transposon.

15 Figure 4 sets out a graph showing the position of insertion in the LT2 genome of the 46 sequenced transposon mutants (position in base pairs in increasing number order against number of transposons). From the graph it can be seen that there is a fairly random distribution of insertions throughout the genome.

20 Figure 5 sets out a diagram of each end of the transposon showing the relative position of the iPCR oligonucleotides with the restriction endonuclease cut sites and RNA polymerase promoters in transposed chromosomal DNA, which has been digested and religated.

Figure 6 sets out a schematic diagram of the ligation capture method of recovering the ends of the transposon.

25 Figure 7 sets out array hybridisation results comparing input and output pool data. Array Images, panel a, reveals comparable sections of the scanned microarrays resulting from the hybridisation of the labeled RNA target generated from the input and output pool restricted DNA. Sets of probes corresponding to three transposon mutants (a set of probes refers to probes synthesised in both the sense and anti-sense  
30 directions around the point of transposon insertion. These are shown as horizontal

lines above, sense probes, and below, anti-sense probes, the disrupted locus), 1  
(corresponding to probes encompassing a transposon insertion within the *aroA*  
gene), 2 (corresponding to probes encompassing a transposon insertion within gene  
X) and 3 (corresponding to probes encompassing a transposon insertion within an  
5 intergenic region) are boxed in the input panel and the data extracted from the input  
and output arrays are compared in the adjacent panel b, Extracted Data. In panel b,  
dashed vertical lines shown between the sense and anti-sense probes refer to the  
position of *RsaI* restriction endonuclease recognition sequences. Boxes above and  
below the black line indicate genes either in the sense or anti-sense direction,  
10 respectively, relative to the published LT2 genome sequence.

**Description of the sequence listing**

SEQ ID NO: 1 sets out the sequence of the "Gene Kelly" transposon.

15 SEQ ID NO: 2 sets out the sequence of primer 97, which was used in the  
construction of the "Gene Kelly" transposon.

SEQ ID NO: 3 sets out the sequence of primer 98, which was used in the  
construction of the "Gene Kelly" transposon.

SEQ ID NO: 4 sets out the sequence of primer 107, which can be used to  
carry out iPCR in a protocol for generating RNA run-offs.

20 SEQ ID NO: 5 sets out the sequence of primer 115, which can be used to  
carry out iPCR in a protocol for generating RNA run-offs.

SEQ ID NO: 6 sets out the sequence of primer 116, which can be used to  
carry out iPCR in a protocol for generating RNA run-offs.

25 SEQ ID NO: 7 sets out the sequence of primer 108, which can be used to  
carry out iPCR in a protocol for generating RNA run-offs.

SEQ ID NO: 8 sets out the sequence of primer 117, which can be used to  
carry out iPCR in a protocol for generating RNA run-offs.

SEQ ID NO: 9 sets out the sequence of primer 118, which can be used to  
carry out iPCR in a protocol for generating RNA run-offs.

SEQ ID NO: 10 sets out the sequence of primer 113, which can be used in a protocol for ligation capture recovery of "Gene Kelly" transposon ends.

SEQ ID NO: 11 sets out the sequence of primer 114, which can be used in a protocol for ligation capture recovery of "Gene Kelly" transposon ends.

5

### Detailed Description of The Invention

The invention relates to a new transposon which is suitable for use in methods for the identification of essential and conditional essential genes. The transposon has been named the "Gene Kelly" transposon.

10 The transposon of the invention is typically a modified *Tn5* transposon, although, in principle, any transposon may be modified so as to prepare a transposon according to the invention. The transposon of the invention has a combination of features which make it a versatile tool for use in a number of protocols for the identification of essential and conditional essential genes. We refer to these methods  
15 as transposon mediated differential hybridisation (TMDH) techniques.

A transposon of the invention comprises an RNA polymerase recognition site (sometimes referred to as an RNA polymerase recognition sequence) and a homing endonuclease recognition site (sometimes referred to as a homing endonuclease recognition sequence).

20 Typically, the RNA polymerase recognition site is located proximal to an end of the transposon, for example adjacent to mosaic ends (if the transposon has them). The RNA polymerase recognition site is typically oriented so that it directs transcription out of the transposon itself. Thus, DNA sequence flanking the integration site of the transposon may be transcribed.

25 These transcribed sequence originate from DNA sequence flanking a transposon insertion site. Such DNA sequences are therefore susceptible to insertion and are unlikely to represent essential gene sequences.

Sequences flanking a transposon insertion site may therefore be isolated from a library of transposon insertion mutants (generated using a transposon of the  
30 invention) and hybridised with an oligonucleotide array which comprises probes

corresponding to open reading frames from an organism to be studied. If the library of insertion mutants comprises a transposon insertion in all of the non-essential genes of the organism, any probe in the oligonucleotide array to which none of the flanking sequences hybridise is likely to be a good candidate for originating from an essential gene. Typically, oligonucleotide arrays suitable for use with a transposon comprise probes corresponding to all of the open reading frames from the organism in question and therefore potentially all of the essential genes of an organism may be identified simultaneously.

Typically, a transposon of the invention comprises two RNA polymerase recognition sites located proximal to the ends, typically to the opposite ends, of the transposon. Preferably, both RNA polymerase recognition sites point out of the transposon, i.e. are capable of directing transcription of DNA sequence flanking the transposon insertion site.

Preferred transposons of the invention comprise two diverse (different) RNA polymerase recognition sites, although the two sites may be the same. The use of two RNA polymerase recognition sites allows two separate pools of RNAs to be isolated from a library of Gene Kelly insertion mutants. One pool will correspond to DNA sequences flanking one side of the transposon insertion site and the other pool will represent sequences flanking the other side of the transposon insertion site (these may be referred to as right- and left-hand pools). The generation of these two separate pools may help to minimise the risk of an essential gene being incorrectly assigned as a non-essential gene. This is explained in more detail below.

A transposon of the invention also comprises a homing endonuclease recognition site. Homing endonucleases are rare cutters, especially in bacterial DNA. Incorporation of recognition sites for such endonucleases into a transposon effectively permits the introduction of these sites into the genome being studied. Transposed DNA may be digested with the appropriate homing endonuclease and the resulting ends (if none are present in the bacterial genome) should therefore all originate from the Gene Kelly transposon. The fragments resulting from digestion with a homing endonuclease may then be digested with a restriction endonuclease

which cuts in the genome of organism being studied. The resulting transposon:flanking sequence fragments may be rescued using a ligation-capture technique described below, allowing the rapid and selective purification of regions of the genomic DNA of the organism being studied which originate from a site of  
5 transposon insertion. Such regions can be used in hybridisation experiments with oligonucleotide arrays as outlined above and as described in more detail below.

Preferably, if the transposon comprises two RNA polymerase recognition sites, it will also comprise two homing endonuclease recognition sites. Typically, if two homing endonuclease recognition sites are present, they will be diverse  
10 (different) homing endonuclease recognition sites. However, they may be the same endonuclease recognition site. The use of two, typically diverse, homing endonuclease recognition sites in combination with two, typically diverse, RNA polymerase recognition sites may allow two separate pools of sequences flanking either side of the inserted transposons to be isolated separately i.e. a left-hand pool  
15 and a right-hand pool of flanking sequences may be separated. The generation of these two pools may help to minimise the risk of an essential gene being incorrectly assigned as a non-essential gene. This is explained in more detail below.

In addition, a transposon of the invention may incorporate a bacterial origin of replication. This allows plasmid-rescue of the complete transposon to be carried  
20 out (plus the flanking regions of chromosomal DNA around the insertion site). This may be achieved by digestion of genomic DNA isolated from a library of transposon insertion mutants (with a restriction endonuclease that does not cut in the transposon sequence or at least in the bacterial origin of replication in the transposon sequence), religation and then transformation into a strain of bacteria in which the origin of  
25 replication will function. A suitable bacterial origin of replication is the R6k origin of replication.

A transposon of the invention thus comprises two critical features: (i) an RNA polymerase recognition site; and (ii) a homing endonuclease recognition site. Optionally, a bacterial origin of replication may be present. A more preferred  
30 version of the Gene Kelly transposon comprises two diverse RNA recognition sites

and two diverse homing endonuclease recognition sites. The full sequence of a preferred Gene Kelly transposon is set out in Figure 2 and SEQ ID NO: 1.

Transposons, sometimes called transposable elements, are mobile polynucleotides. The term transposon is well known to those skilled in the art and includes classes of transposons that can be distinguished on the basis of sequence organisation, for example short inverted repeats at each end; directly repeated long terminal repeats (LTRs) at the ends; and polyA at 3' ends of RNA transcripts with 5' ends often truncated. Some types of virus also integrate into the host genome, for example retroviruses, and may therefore be used to generate libraries of insertion mutants. However, transposons are typically preferred to viruses because issues of safety related to pathogenicity may be avoided.

A transposon of the invention comprises an RNA polymerase recognition site (typically two) and a homing endonuclease recognition site (typically two). Any suitable transposon may be modified to produce a transposon of the invention. Suitable transposons for use in bacteria which can be modified to generate a Gene Kelly transposon include *Tn3*,  $\gamma\delta$ , *Tn10*, *Tn5*, *TnphoA*, *Tn903*, *Tn917*, Bacteriophage Mu and related viruses. Any of the above mentioned transposons may be modified to generate a transposon of the invention. Different parts of different transposons may be mixed and matched in a transposon of the invention. A particular preferred transposon for use in the invention is a modified *Tn5* transposon.

Suitable transposons for use in fungi which can be modified to generate a transposon of the invention include the *Ty1* element of *Saccharomyces cerevisiae*, the filamentous fungi elements (the filamentous fungi include agriculturally important plant pathogens such as *Erysiphe graminis*, *Magnaporthe grisea*) such as *Fof1/Pogo*-like and *Tc1/Mariner*-like elements (see Kempen and Kuck, 1998, Bioessays 20, 652-659 for a review of such elements).

Suitable transposons for use in plants which can be modified to generate a transposon of the invention include *Ac/Ds*, *Tam3* and other *Tam* elements, *cin4* and *spm*.

Suitable transposons for use in animals which can be modified to generate a transposon of the invention include *P* and *hobo* which may be used in *Drosophila* and *Tc1* which can be used in *Caenorhabditis elegans*.

5 A preferred transposon of the invention is one which carries an antibiotic resistance gene (which may be useful in identifying mutants which carry a transposon) conferring resistance to, for example, kanamycin, streptomycin and bleomycin.

A transposon of the invention may comprise one, two or more recognition sites for an RNA polymerase. Preferred recognition sites are those for which the  
10 corresponding RNA polymerase is highly selective for initiation. Other preferred recognition sites are those for which the corresponding RNA polymerase does not initiate transcription from sequences of the organism being studied. Preferred examples of RNA recognition sites are those recognised by bacteriophage RNA polymerases, for example the recognition site for T7 RNA polymerase, T3 RNA  
15 polymerase or SP6 RNA polymerase, in particular the T7 RNA polymerase recognition site. A preferred Gene Kelly transposon will thus carry two of a T7 RNA polymerase recognition site, an SP6 RNA polymerase recognition site or a T3 RNA polymerase recognition site, for example a T7 RNA polymerase recognition site and an SP6 RNA polymerase recognition site. The recognition sites for these specific  
20 RNA polymerases are well known to those skilled in the art.

The RNA polymerase recognition site may appear anywhere within a transposon for use in the invention. However, typically the RNA polymerase recognition site will be located proximal to one end of the transposon, i.e. proximal to one IS/ME. Typically, the 3' end of the RNA polymerase recognition site will be  
25 situated from one to 30, for example from five to twenty base pairs away from the 5' end of one of the IS/ME.

Preferred transposons of the invention comprise two RNA polymerase recognition sites, which generally will be different RNA polymerase recognition sites. For example, a transposon may comprise a T7 RNA polymerase recognition  
30 site and an SP6 RNA polymerase recognition site.



A transposon of the invention may also comprise more than two RNA polymerase recognition sites, for example three or four RNA recognition sites. More than two recognition sites may be useful in a situation where the genome of an organism being studied possesses recognition sites for one of the RNA polymerase recognition sites present in the transposon. Thus, different RNA polymerase sites in one transposon may be suitable for use in different genomes. The specific RNA polymerase recognition sites used may vary with the particular organism being studied. A single transposon may therefore be suitable for use in a number of different organisms.

A transposon of the invention comprises a homing endonuclease recognition site. Preferably, two such sites are present which may be the same or diverse. Homing endonucleases are also known as intron or intein encoded endonuclease. They are encoded by genes with mobile, self-splicing introns or inteins (protein introns). Any homing nuclease recognition site may be used, for example I-*SceI*, PI-*PspI* or I-*PpoI*, or preferably a combination of any two thereof.

A homing endonuclease recognition site may be located anywhere in the transposon, but typically it is situated 5' to an RNA polymerase recognition site, i.e. further into the transposon than the RNA polymerase recognition site. Preferred transposons of the invention may comprise two homing endonuclease recognition sites which generally will be different homing endonuclease recognition sites, for example a I-*SceI* and a PI-*PspI* recognition site. This is usually the case where the transposon comprises two RNA polymerase recognition sites.

A transposon of the invention may, however, comprise more than two homing endonuclease recognition sites, for example three or four homing endonuclease recognition sites. More than two recognition sites may be useful in a situation where the genome of an organism being studied possesses recognition sites for one of the homing endonuclease recognition sites present in the transposon. Thus, different homing endonuclease recognition sites in one transposon may be suitable for use in different genomes. The specific homing endonuclease recognition sites used in the transposon may vary with the particular organism being studied. A

single transposon may therefore be suitable for use in a number of different organisms.

Typically, a transposon of the invention will comprise the same number of RNA polymerase recognition sites as homing endonuclease recognition sites, ideally two of each. Each homing endonuclease recognition site will typically be located 5' to an RNA polymerase recognition site, for example such that the 3' end of the homing endonuclease recognition site is from one to 30, for example, from five to twenty base pairs away from the 5' end of one of an RNA polymerase recognition site.

A transposon of the invention may also comprise a bacterial origin of replication. A preferred example of a suitable bacterial origin of replication is the R6k origin of replication. The R6k origin of replication is capable of functioning in a *pir*<sup>+</sup> strain of bacteria.

A transposon of the invention may be used in methods for the identification of essential or conditional essential genes, i.e. use of a transposon of the invention in a method for the identification of an essential gene or a conditional essential gene is provided according to the invention. The methods described below for the identification of essential or conditional essential genes using a transposon of the invention can conveniently be referred to as transposon mediated differential hybridisation (TMDH). TMDH techniques are described in detail in WO-A-01/07651 (PCT/GB00/02879) and the transposon of the invention may be used in any of the methods set out therein.

In methods for the identification of essential gene, typically the first step is the provision of a library of transposon insertion mutants. Libraries of insertion mutants using a transposon of the invention may be generated according to any method known to those skilled in the art. For example, libraries of bacterial transposon insertion mutants can be constructed using either plasmid or bacteriophage vectors containing the transposon and a selectable marker. Bacteriophage  $\lambda$ , eg.  $\lambda$ *TnphoA* can be used to infect a suitable recipient bacterial strain, for example *E. coli* XAC. This *E. coli* strain has a suppressor mutation which

prevents the bacteriophage from replicating and subsequently lysing and also contains an antibiotic resistance gene to allow selection of colonies containing transposed chromosomal DNA. The vector contains mutation(s) preventing integration of the  $\lambda$  chromosome into the bacterial host chromosome and thus the growth of false positive colonies without a mutated *E. coli* gene is prevented. Cultures of the recipient strain are grown in enriched medium (eg. Luria Broth) and cells in mid log phase of growth are infected with the  $\lambda$  transposon vector for 1 hour at 37°C. Aliquots of the infected cells are plated out on L-agar supplemented with the appropriate selective antibiotic and grown overnight at 37°C. These colonies constitute a transposon library and can be further analysed by the TMDH procedure described in this application.

Alternatively, transposome complexes comprising the transposon in a complex with a transposase may be generated and electroporated into a suitable electrocompetent host. Suitable techniques for preparing transposomes and for electroporating transposomes into host cells are well known to those skilled in the art.

Growth of such libraries results in the generation of potentially thousands of insertion mutants all of which mutants carry insertion that are, of necessity, in genes that (when mutated) do not result in the death of the cell ie. are non-essential genes.

Each mutant in a suitable transposon insertion library may carry one transposon insertion. However, a mutant may carry more than one transposon insertion, for example two, three, four, five, ten or twenty transposon insertions. A transposon insertion mutant library suitable for use in the invention will comprise at least one transposon insertion mutant for at least 60%, at least 70%, typically at least 80%, preferably at least 90%, more preferably at least 95%, even more preferably at least 99%, or most preferably substantially all of the non-essential genes in the organism being studied. Preferably the library will be a saturating library, i.e. the library comprises a transposon insertion mutant for substantially all genes of the organism that when mutated give rise to viable organisms.

A transposon insertion could be in an open reading frame of a gene or in a regulatory sequence of gene.

Any non-essential gene in the transposon insertion library may be represented by more than one insertion mutant, for example two, three, four, five or up to ten insertion mutants, each carrying transposon insertions at the same or different sites in the non-essential gene or carrying insertions at the same site in different orientations.

5 Preferred libraries will have, on average, more than one different transposon insertion mutant for each non-essential gene represented in the library, for example at least two on average, at least four on average, at least 5 on average or at least 10 on average different transposon insertion mutants for each non-essential gene represented in the library.

10 Some regions of a particular genome may be inaccessible to insertion by a particular transposon, for example because of a particular secondary or tertiary structure which is inaccessible to a particular transposon. Thus it may be advantageous to combine two transposon libraries, thereby increasing the probability of obtaining transposon insertions in a greater number of genes. For example, in the  
15 case of bacterial libraries, a library generated with Gene Kelly transposons based on a *Tn5* transposon and a library generated with a Gene Kelly transposons based on a *Tn10* transposon could, for example, be combined.

Generally, flanking sequence will be isolated from at least 60%, for example at least 70%, at least 80%, preferably at least 90%, more preferably at least 95% and  
20 most preferably at least 99% of the transposon insertion mutants in a particular library of mutants.

In the method of the invention chromosomal DNA is prepared from the library of transposon insertion mutants. Techniques for the isolation of chromosomal DNA, alternatively referred to as genomic DNA, are well known to those skilled in  
25 the art. The transposons of the invention allow for a number of different techniques to be used for the generation of RNA target sequences from the isolated genomic DNA.

In one version of TMDH, the chromosomal DNA thus prepared is then digested with a restriction endonuclease. The restriction endonuclease is one which  
30 is capable of cutting at a recognition site which is located in the transposon at a

position 5' to the RNA polymerase recognition site (which is located in the transposon) and 3' to the RNA polymerase recognition site in the chromosomal DNA flanking the transposon insertion site.

In a modification of this protocol, two restriction endonucleases may be used:

- 5 a first restriction enzyme which cuts 5' to the RNA polymerase recognition site (which is located in the transposon) in the transposon itself; and a second restriction enzyme which cuts 3' to the RNA polymerase recognition site in the chromosomal DNA flanking the transposon insertion site. If two restriction enzymes are used in this way, they may be used simultaneously or one after the other in either order.

- 10 The exact restriction enzyme(s) to be used will depend on the sequence of the transposon. However, typically an restriction endonuclease is used which has recognition sites that appear frequently within the genome of the organism being studied. Thus, a series of DNA fragments is generated, some of which comprise an RNA polymerase recognition site fused to a portion of flanking sequence, i.e. non-  
15 essential gene sequence.

Generally, suitable restriction endonucleases will have six base pair, five base pair or preferably four base pair recognition sequences. Suitable examples of four base pair cutters are set out in Table 1 below:

20 Table 1. Examples of 4bp recognition type II restriction endonucleases suitable for use in TMDH

Enzyme	Recognition Site	Enzyme	Recognition Site
<i>AccI</i>	C'CGC GGC <sub>1</sub> G	<i>MseI</i>	T'TAA AAT <sub>1</sub> T
<i>AluI</i>	AG'CT TC <sub>1</sub> GA	<i>MspI</i>	C'CGG GGC <sub>1</sub> C
25 <i>BfaI</i>	C'TAG GAT <sub>1</sub> C	<i>NlaIII</i>	'CATG GTAC <sub>1</sub>
<i>BstXI</i>	CG'CG GC <sub>1</sub> GC	<i>RsaI</i>	GT'AC CA <sub>1</sub> TG

<i>DpnI</i>	<sup>1</sup> GATC CTAG <sub>1</sub>	<i>Sau3a</i>	<sup>1</sup> GATC CTAG <sub>1</sub>
<i>HaeIII</i>	GG <sup>1</sup> CC CC <sub>1</sub> GG	<i>TaqI</i>	T <sup>1</sup> CGA AGC <sub>1</sub> T
<i>HinPI</i>	G <sup>1</sup> CGC CGC <sub>1</sub> G	<i>Tsp509</i>	<sup>1</sup> AATT TTAA <sub>1</sub>
<i>HhaI</i>	GCG <sup>1</sup> C C <sub>1</sub> GCG		

5

The resulting fragments comprise an RNA polymerase site adjacent to non-essential gene sequence. The fragments may optionally be size selected. If size selection is carried out, fragments with a size of from about 100 bp to about 2000bp or preferably of from about 200 bp to about 600 bp may be isolated, for example from a gel, and purified. The smaller the fragments isolated, the smaller the chance of the RNA target sequences including sequences from genes which lie next to genes which have been interrupted by transposons. If such adjacent sequences were from essential genes, there is the possibility that essential gene sequences could be identified as non-essential gene sequences. Thus, size fractionation may reduce the amount of false non-essential gene sequences.

10

15

RNA target sequences are generated from the DNA (host organism) sequences that flank the transposons, i.e. those regions corresponding to non-essential gene sequences. That is, the transposon:flanking sequence fragments are then used to generate the RNA sequences. Thus, following digestion, the transposon:flanking sequence fragments (the "target") may be transcribed. Optionally, the transposon:flanking sequence fragments may be amplified prior to transcription, for example by PCR. Preferably this is carried out by iPCR (inverse PCR).

20

Transcription is carried out by *in vitro* transcription from the RNA polymerase recognition sequence. Techniques for carrying out *in vitro* transcription are well known to those skilled in the art and any suitable technique may be used. In essence, an RNA polymerase and ribonucleotides are used.

25

The RNA target sequences so-generated may then be hybridised with oligonucleotide arrays. Alternatively, the RNA target sequences may be reverse transcribed to produce cDNA target sequences. Reverse transcription may be primed using an oligonucleotide having a sequence based on the transposon sequence immediately 3' to the site of transcription initiation. Techniques for carrying out reverse transcription are well known to those skilled in the art and any suitable technique may be used. In essence, a reverse transcriptase and deoxyribonucleotides are used.

Preferably, the transcription reaction or the reverse transcription reaction is carried out in the presence of one or more labelled ribonucleotides or one or more labelled deoxyribonucleotides respectively, so that the resulting RNA or cDNA target sequences are labelled.

Suitable labels include radioactive labels, for example  $^{32}\text{P}$ ,  $^{33}\text{P}$  or  $^{35}\text{S}$ , or non-radioactive labels, for example an enzyme, a fluorescent label or biotin.

Fluorescent labels are preferred, for example a water-soluble fluorescent dye such as Cy3<sup>TM</sup> or Cy5<sup>TM</sup> or a fluorescein-tagged compound such as FluorX<sup>TM</sup> (the NHS ester of carboxyfluorescein with an extended linker arm), fluorescein isothiocyanate (FITC) or 5-([4,6-Dichlorotriazin-2-yl]amino)fluorescein (DTAF). Generally, it will only be necessary to have one of the four ribonucleotides or deoxyribonucleotides labelled.

The techniques described above allow the isolation of sequences flanking the transposons in a library of transposon insertion mutants. Thus, a pool of flanking sequences is generated collectively referred to as the RNA (or cDNA) target sequences. Although fragments in the pool are generated from only one side of the transposons, a transposon is capable of inserting at any particular locus (that can be disrupted) in either orientation. Thus, particularly in a saturating transposon insertion library, many loci will be represented by mutants carrying insertions in both orientations. Therefore, the RNA (or cDNA) target sequences generated according to the TMDH method of the invention will, for many loci, comprise flanking sequence in both orientations.

In a modification of this technique, the fragments comprising the RNA polymerase site fused to non-essential gene sequence may be amplified.

Amplification may be carried out by ligating linkers, preferably vectorette units, to the fragments. If linkers are ligated to the fragments, the resulting fragments  
5 may be re-purified for example through a gel or by using spun-column chromatography. PCR may then be carried out using the fragments as templates with a primer pair comprising an oligonucleotide specific for a transposon sequence and a second oligonucleotide specific for a linker (eg. a vectorette) sequence. The use of transposon- and vectorette-specific PCR primers results in the specific amplification  
10 of sequences that are adjacent to the sites of transposon insertion.

Alternatively, the fragments may be amplified by cycle primer extension. The use of a suitable labelled oligonucleotide primer can allow the amplification of sequences adjacent to the sites of transposon insertion. Those labelled amplified sequences can be used directly in hybridisation experiments.

15 Alternatively, the fragments may be amplified by inverse PCR (iPCR). Thus, the fragments may be self-ligated and subsequently amplified using transposon specific primers.

Suitable techniques for carrying out self-ligation are well known to those skilled in the art. Any suitable ligase may be used, for example T4 DNA ligase.  
20 Ligation reactions may be carried out for from 6 to 24 hours, for example from 12 to 16 hours at a temperature of from 10°C to 20°C, for example at about 16°C.

Self-ligated molecules are then amplified using iPCR. Techniques for carrying out iPCR are well known to those skilled in the art and may be carried out according to any suitable technique. Typically, iPCR is carried out using two  
25 oligonucleotides which bind divergently at a location 5' to the RNA polymerase recognition site. Preferably the oligonucleotides bind divergently to a location which is 3' to the restriction endonuclease recognition site in the transposon. That is, the two oligonucleotide recognition sites are preferably located on the transposon between the restriction endonuclease recognition site and the RNA polymerase recognition  
30 site.



When using iPCR techniques, there is the possibility that, a "stuffer" fragment may ligate into the self-ligation reaction, which will be amplified along with the transposon-disrupted sequence. If this material were to be used in subsequent generation of the RNA target sequences, the stuffer sequence could create

- 5 non-specific background signal as it would also be hybridized to the high density array. In order to remove this stuffer fragment, the sequences amplified in iPCR can be redigested with whichever enzyme was used to isolate the transposon-flanking sequence fragments in the first place. This results in the release of the stuffer fragments which can be removed from the transposon-flanking sequence fragments.
- 10 Removal of the stuffer fragments can be facilitated if a biotinylated primer is used in iPCR. The biotinylated transposon-flanking sequence fragments can then be removed from the stuffer fragments using a magnetic-bead-streptavidin conjugate.

- Additional methods for amplifying transposon-flanking sequence fragments include, for example, splinkerette-PCR, targetted gene walking PCR, restriction site
- 15 PCR, capture PCR, panhandle PCR and boomerang DNA amplification (for a review of these techniques see Hui *et al.*, Cell Mol. Life Sci. 54 (1998) 1403-1411).

- It is possible that the particular restricted endonuclease used will not cut within the gene in which the transposon is inserted, or cuts at a large distance, for example more than 2kb, away from the insertion site. Therefore, if size selection is
- 20 carried out, sequences from these genes may be lost. Thus, the generation of fragments may be carried out several times, each time using a different restriction endonuclease and the resulting fragments may subsequently be pooled. The greater the number of enzymes used to make fragments, the greater the likelihood of sequences from non-essential genes being represented in the final pool of fragments.

- 25 In a further modification of TMDH method, the chromosomal DNA isolated from a transposon insertion library may be divided into a number of aliquots. Those aliquots may then each be separately digested with a different restriction endonuclease which is capable of cutting at a recognition site which is located in the transposon at a position 5' to the RNA polymerase recognition site and in the
- 30 chromosomal DNA flanking the transposon 3' to the RNA polymerase recognition

site (which is in the transposon). The chromosomal DNA may be separated into, for example two, three, four, five or ten aliquots which are each separately digested with a different restriction endonuclease. Preferred restriction enzymes are as set out in Table 1 above.

5        Thus, for example, two or three aliquots of the chromosomal DNA may be separately digested with different suitable restriction endonucleases, for example two or three of *HaeIII*, *HhaI*, *Hpych4IV* and *RsaI*.

10        If the TMDH protocol is used in this modified format, the different aliquots may be repooled after digestion and treated together in the subsequent steps of TMDH. Alternatively, the digested aliquots may be treated separately in the subsequent steps. If this TMDH format is adopted, a number of pools of RNA target sequences result. Each pool of RNA target sequences may be labelled with a different, for example fluorescent, label.

15        In an alternative protocol for the preparation of RNA/cDNA target sequences, the genomic DNA isolated from a library of transposon mutants is digested with a homing endonuclease. Homing endonuclease recognition sites are rare and therefore any "ends" generated by digestion with a homing endonuclease should originate from the transposon. Fragments resulting from digestion with a homing endonuclease are then further digested with a restriction endonuclease which does not cut in the transposon, for example a restriction enzyme as described above, but which does cut within the genomic sequence flanking the transposon ends (i.e. flanking the transposon insertion site). The resulting transposon:flanking sequence fragments may then be rescued by annealing a biotinylated linker to them and then isolating the biotinylated transposon:flanking sequence fragments with streptavidin-coated particles, for example streptavidin-coated magnetic beads. The linker anneals to the homing endonuclease recognition site end of the fragments.

20       

25       

Alternatively the ends bearing the homing endonuclease recognition site may be rescued by labelling with digoxigenin and isolating the labelled fragments with an antibody raised against digoxigenin. The step of digestion with a restriction enzyme

may be carried out after the transposon:flanking sequence fragments have been isolated.

The use of homing endonucleases may allow the step of isolating genomic DNA from a library of transposon mutants to be eliminated. Thus, the library of mutants may be digested directly with a homing endonuclease. Typically, an extract of the library may be generated. For example, if the library is a bacterial library, the bacterial cells may be lysed before digestion with a homing endonuclease is carried out. Once digestion with a homing endonuclease has been carried out, transposon ends (transposon:flanking sequence fragments) may be recovered as described above.

10 The transposon:flanking sequence fragments are then used to generate the RNA target sequences by carrying out *in vitro* transcription from the RNA polymerase recognition site. *In vitro* transcription can be carried out as described above. If, after cutting with the homing endonuclease, a further restriction enzyme is not used to cut within the flanking sequences, *in vitro* transcription may be carried  
15 out in the presence of a dideoxyribonucleotide. That allows transcription to be terminated, reducing the risk of the transcribed sequence comprising portions of genes adjacent to the gene into which insertion has taken place.

The sequences which comprise the RNA target sequences (whichever of the methods described above is used to generate them) may be used for hybridisation  
20 with oligonucleotide arrays. Oligonucleotide arrays used in the TMDH protocol of the invention are preferably high information content arrays.

Oligonucleotide arrays suitable for use in the invention may comprise sequences from one or more loci of a genome. Preferably suitable oligonucleotide arrays will represent at least 80% of all open reading frames (ORFs), more preferably  
25 at least 90% of all ORFs, for example 95% of all ORFs, even more preferably 99% of all ORFs or substantially all ORFs of the genome represented on the oligonucleotide array.

By high information content array is meant an array in which there are a high number of probes covering the locus, loci or genome represented by the array. For  
30 example, in a high information content array there may be a probe, for example, for

every 30 to 500 base pairs of the locus, loci or genome represented by the array. Preferably there will be a probe, for every 60 to 250 base pairs of locus, loci or genome represented in the array, for example about every 100 base pairs. Probes may overlap, for example by 1, 2, 3, 4, 5, up to 10, up to 20, up to 30, up to 40 or up to 50 bases.

The oligonucleotide probes on the array are, for example, from about 8 or 9 to about 150 nucleotides in length, preferably from about 30 or 50 to about 100 nucleotides in length or more preferably about 60 nucleotides in length.

The oligonucleotide probes used in the array will typically be designed on the basis of the wild type sequence of the organism being studied. The oligonucleotide probes may be designed so that each probe has minimal or substantially no cross-hybridisation with other sequences in the genome from which the probes originate. The BLAST program can be used to design suitable probes (Altschul *et al.*, J. Mol. Biol. 215, 403-410).

Methods for making oligonucleotide arrays are well known to those skilled in the art.

Probes which show no hybridisation or substantially no hybridisation (there may be a low level of background non-specific hybridisation) with the RNA target represent sequences that are unlikely to have been disrupted by a transposon insertion event and consequently are strong candidates for sequences corresponding to essential genes.

However, it is theoretically possible for oligonucleotide probes within the 5' or 3'-termini of essential genes to show a hybridisation signal with the TMDH protocol. For example, if a transposon insertion occurs in a non-essential gene adjacent to an essential gene, RNA target sequences may be generated from this transposon corresponding to both non-essential and essential gene sequences as a result of restriction sites lying within the essential gene. The resulting labelled target will not only comprise DNA corresponding to the non-essential gene (that has been disrupted), but will also extend into the adjacent essential gene up to the restriction site. The result of hybridising this labelled target to the oligonucleotide array will be

appear as "bleed through" of signal to probes on either the 5' or 3' end of the essential gene, up to the restriction site used for the TMDH protocol.

To address this potential source of mis-assignment of essential genes, the restriction endonuclease digestion TMDH protocol described above may be carried  
5 with more than one aliquot of the isolated genomic DNA, for example two or three, whereby each aliquot is digested with a different restriction endonuclease (which have different recognition motifs). The more aliquots digested, with more restriction sites that are used to generate target sequences, the more statistically unlikely it is that all of them will result in labelled RNA target sequences that "bleed through" into  
10 essential genes. The pools of RNA target sequences derived from the different digestions can be hybridised to the same or, preferably, different oligonucleotide arrays if they were generated using different labels, or alternatively may be hybridised to copies of the same or, preferably, a different array. The analysis of the resulting multiple array hybridisation patterns will remove any ambiguity on the site  
15 of transposon insertion.

A different modification to the TMDH protocol, applicable to both the standard restriction endonuclease and the homing endonuclease approaches, to minimize the mis-assignment of essential genes as non-essential gene is to isolate two pools of RNA target sequences which each originate from different sides of the  
20 transposons. This approach is illustrated in Figures 5 and 6. Figures 5 and 6 show Gene Kelly transposons which comprise two RNA polymerase recognition sequences (although in Figure 6 the two ends are shown superimposed).

In figure 5 one pool of RNA target sequences (from one side of the transposons) is generated by carrying out *in vitro* transcription using T7 polymerase  
25 and a second pool of RNA target sequences (from the other side of the transposon) is generated by carrying out *in vitro* transcription using T3 or SP6 polymerase.

Similarly, in figure 6 one pool of RNA target sequences (from one side of the transposons) is generated by carrying out *in vitro* transcription using T7 polymerase and a second pool of RNA target sequences (from the other side of the transposon) is  
30 generated by carrying out *in vitro* transcription using T3 or SP6 polymerase. The

ends lying 5' to the RNA polymerase recognition site (which are rescued using streptavidin coated particles) are generated via digestion with homing endonucleases. The homing endonuclease recognition site associated with each RNA polymerase recognition site may be the same or different homing endonuclease recognition sites.

5       The two pools of RNA target sequences can be hybridised to the same oligonucleotide array if they were generated using different labels, or alternatively each may be hybridised to a separate copy of the same array. Probes in the oligonucleotide array which shows no hybridisation to either pool are likely to correspond to essential genes.

10       Where an essential gene sequence is isolated in one of the RNA/cDNA pools because it lies close to a non-essential gene sequence flanking a transposon insertion site, hybridisation to a probe on the oligonucleotide array will be observed even though that probe corresponds to an essential gene. However, that probe will show no hybridisation with the other pool of RNA target sequences which comprise the  
15 flanking sequence from the other side of the transposon. Thus, in this type of TMDH, a probe in the oligonucleotide array to which at least one of the pools of RNA target sequences does not hybridise is likely to correspond to a gene that has not been disrupted by a transposon and may therefore be assigned as an essential gene.

      In the methods described above (and also in those described below for the  
20 identification of conditional essential genes), the pools of RNA sequences may be directly hybridised to arrays as set out above. Alternatively, before hybridisation is carried out, the pools of RNA sequences may be subjected to reverse transcription to generate pools of cDNAs. The sequence of the particular transposon of the invention used to generate the library of mutants may be used to design oligonucleotide  
25 primers suitable for priming reverse transcription or, alternatively, random primers may be used. A label may be included in the reverse transcription reaction so that labelled cDNA pools are generated. The cDNA pools may be then be hybridised to arrays as is described above in relation to RNA pools.

      The TMDH methods described above may also be used for the identification  
30 of conditional essential genes. Conditional essential genes are those which are not

absolutely essential for bacterial survival, but are essential for survival in particular environments e.g. for growth/proliferation, in a host (in the case of a pathogenic bacterium) or for survival at elevated temperatures. Such environments are described here as conditional restraints.

5        In order to isolate conditional essential genes, a library of transposon mutants is generated under control conditions (eg. growth at 37°C in complete media). The library of mutants is then subjected to some conditional restraint. For example, the library of mutants can be inoculated in a suitable host, if it is a pathogen. Alternatively, the library of mutants can be grown at an elevated temperature. After  
10       the library of mutants has been subjected to the conditional restraint it can be recovered.

      The library of mutants may be recovered by, for example, recovering tissue such as the liver and/or spleen from a host and plating out an extract derived from that tissue on growth medium. All surviving colonies on the plate represent mutants  
15       where a transposon insertion has occurred in a non-essential sequence. The surviving colonies can be pooled to give an output library of mutants which can then be subjected to one of the TMDH methods set out above.

      Alternatively, non-essential DNA sequences may be recovered directly from tissue (such as the liver and/or spleen) of an infected host without an intervening step  
20       of plating out an extract of the isolated tissue. In this regard, the presence of one, or preferably two, homing endonuclease recognition sites in the transposon is crucial. Thus, the tissue may be subjected to digestion with a homing endonuclease for which there is a corresponding recognition site in the relevant transposon. Typically, the tissue would be homogenised before digestion. Transposon ends (i.e.  
25       transposon:flanking sequence fragments) may then be recovered from the tissue. This may be achieved by annealing biotinylated linkers to the transposon ends and recovering the resulting biotinylated transposon ends with, for example, streptavidin-coated beads. The isolated transposon:flanking sequence fragments may then be digested with a restriction endonuclease which cuts in the sequence

flanking the transposon insertion site. Alternatively, the fragments may be digested with a restriction endonuclease prior to recovery from the tissue.

The library of mutants that have been exposed to the conditional restraint will lack mutants which carry transposons in those genes essential for growth under the conditional environment, for example growth/proliferation in a host organism.

The control and conditional restraint libraries can then be subjected to the TMDH protocols described above using the a transposon of the invention. Clearly, if transposon:flanking sequence fragments have been isolated directly, for example from a host tissue using capture of, those fragments enter a TMDH protocol at the stage of preparing RNA by transcription from the RNA polymerase site(s).

It is not necessary to use the same TMDH protocol for each library. The two resulting RNA target sequence libraries may then be hybridised separately to high density oligonucleotide arrays. Alternatively they can be hybridised to the same array, if the control and conditional restraint libraries are differentially labelled for example.

Comparison of the results given with the control and the conditional restraint libraries will allow the identification of genes which permit survival in the conditional restraint. Genes identified as essential for survival in the conditional restraint library, but not identified as essential for survival under control conditions should represent genes that are essential for survival under the conditional restraint conditions. In particular, probes which show hybridisation with RNA target sequences from the input library but which show no hybridisation or substantially no hybridisation (there may be a low level of background non-specific hybridisation) with RNA target sequences from the output library are strong candidates for sequences corresponding to conditional essential genes. The same "bleed through" considerations apply as set out above and the modified TMDH protocols for overcoming such "bleed through" may need to be used.

In the case of the analysis of conditional mutations in a pathogen, a library of *Salmonella typhimurium* transposon mutants, for example, can be used to infect a mouse. Following infection, bacteria target to livers and spleens and the course of



infection can be conveniently followed by performing viable bacterial counts on those organs. The bacteria recovered from the livers and spleens can be grown on suitable plates. In the case of the conditional restraint at elevated temperature, a transposon-tagged library can be grown at 42°C.

- 5        Other conditional restraints include growth of antibiotic resistant bacteria in the presence of antibiotics. This may reveal genes which are essential for antibiotic resistance. Such genes would be targets for drugs with the ability to lower bacterial resistance to particular antibiotics. Organisms could be grown in the presence of carcinogens, UV or other agents that cause oxidative stress and thus genes that confer
- 10    resistance to growth under those conditions may be identified.

Potential essential gene sequences and conditional essential gene sequences identified by a TMDH strategy using a transposon of the invention may be verified using a method based on allelic exchange. This technique is particularly suitable for analysis of bacterial genes. PCR primers can be used to generate left- and right-arm

15    sequences corresponding to the target gene sequence and ligated with a kanamycin-resistance encoding gene cassette. The resulting cassette can be introduced into a suicide vector, for example a plasmid-based vector, which is unable to replicate in a host bacterium.

In the case of a candidate essential gene, the resulting construct can be

20    introduced into the bacterial strain from which the candidate gene originates. If the target gene is essential, it should be impossible to isolate allelic-exchange mutants that have a disrupted version of the target gene. In the case of a candidate conditional essential gene, the essential gene can be introduced into the bacterial strain from which the candidate gene originates. Allelic-exchange mutants can be

25    isolated and subjected to growth under the conditional restraint. If the candidate gene is a conditional essential gene, it should not be possible for the allelic-exchange mutants to survive under the conditional restraint.

Similar experiments may be performed for other organisms.

The use of bioinformatics may allow the rapid isolation of further essential

30    and conditional essential genes. A gene identified by TMDH using a transposon of

the invention may be used to search databases containing sequence information from other species in order to identify orthologous genes from those species. Genes so identified can be tested for being essential or conditionally essential using the genetic techniques described above. For example, an *E. coli* gene is identified as essential using a method as described above. This may allow the identification of a putative orthologue from Salmonella. That Salmonella gene may be tested by allelic exchange and the construction of conditional mutants in Salmonella as described above. Further orthologues may be identified in more distantly related organisms, for example from Plasmodium species.

10. Suitable bioinformatics programs are well known to those skilled in the art. For example, the Basic Local Alignment Search Tool (BLAST) program (Altschul *et al.*, 1990, J. Mol. Biol. 215, 403-410. and Altschul *et al.*, 1997, Nucl. Acids Res. 25, 3389-3402.) may be used. Suitable databases for searching are for example, EMBL, GENBANK, TIGR, EBI, SWISS-PROT and trEMBL.

15. Organisms that may be used in the invention are those for which it is possible to carry out transposon mutagenesis and thus, those that can give rise to a library of transposon mutants. Clearly, if the genome is bigger, more mutants will have to be produced in order to give a better chance of achieving saturation mutagenesis. Suitable organisms include prokaryotic and eukaryotic organisms. Suitable prokaryotes include bacteria. Preferred bacteria are those which are animal or human or plant pathogens.

The bacteria used may be Gram-negative or Gram-positive. The bacteria may be for example, from the genera *Escherichia*, *Salmonella*, *Vibrio*, *Haemophilus*, *Neisseria*, *Yersinia*, *Bordetella*, *Brucella*, *Shigella*, *Klebsiella*, *Enterobacter*, *Serratia*, *Proteus*, *Vibrio*, *Aeromonas*, *Pseudomonas*, *Acinetobacter*, *Moraxella*, *Flavobacterium*, *Actinobacillus*, *Staphylococcus*, *Streptococcus*, *Mycobacterium*, *Listeria*, *Clostridium*, *Pasteurella*, *Helicobacter*, *Campylobacter*, *Lawsonia*, *Mycoplasma*, *Bacillus*, *Agrobacterium*, *Rhizobium*, *Erwinia* or *Xanthomonas*. Examples of some of the above mentioned genera are *Escherichia coli* - a cause of diarrhoea in humans; *Salmonella typhimurium* - the cause of salmonellosis in several

animal species; *Salmonella typhi* - the cause of human typhoid fever; *Salmonella enteritidis* - a cause of food poisoning in humans; *Salmonella choleraesuis* - a cause of salmonellosis in pigs; *Salmonella dublin* - a cause of both a systemic and diarrhoeal disease in cattle, especially of new-born calves; *Haemophilus influenzae* - a cause of meningitis; *Neisseria gonorrhoeae* - a cause of gonorrhoea; *Yersinia enterocolitica* - the cause of a spectrum of diseases in humans ranging from gastroenteritis to fatal septicemic disease; *Bordetella pertussis* - the cause of whooping cough; *Brucella abortus* - a cause of abortion and infertility in cattle and a condition known as undulant fever in humans; *Vibrio cholerae* - a cause of cholera; *Clostridium tetani* - a cause of tetanus; *Bacillus anthracis* - a cause of anthrax. Suitable eukaryotes include fungi, plants and animals. Preferred eukaryotes include animal or human parasites and plant pests.

Suitable fungi include the animal pathogens including *Candida albicans* - a cause of thrush, *Trichophyton* spp. - a cause of ringworm in children, athlete's foot in adults. Other suitable fungi include the plant pathogens *Phytophthora infestans*, *Plasmopara viticola*, *Peronospora* spp., *Saprolegnia* spp., *Erysiphe* spp., *Ceratocystis ulmi*, *Monilinia fructigena*, *Venturia inequalis*, *Claviceps purpurea*, *Diplocarpon rosae*, *Puccinia graminis*, *Ustilago avenae*.

Suitable animal parasites include *Plasmodium* spp., *Trypanosoma* spp., *Giardia* spp., *Trichomonas* spp. and *Schistosoma* spp. Other animal parasites include the various platyhelminth, nematode and annelid parasites.

Suitable plant pests include insects, nematodes and molluscs such as slugs and snails.

Suitable plants include monocotyledons and dicotyledons.

Preferred organisms are those for which the entire genome is known and for which it may be possible to construct a high density oligonucleotide array covering the entire genome or all of the open reading frames.

Essential and conditional essential genes, particularly essential genes are targets for drug discovery. That is, essential and conditional essential genes of bacteria and the polypeptides which they encode may represent targets for

antibacterial substances, for example. Similarly essential and conditional essential genes of fungi and eukaryotic parasites, pests and plants and the proteins which they encode may represent targets for fungicides, antiparasitics, pesticides and herbicides respectively. Fungicides may have both animal and plant applications. Additionally,  
5 conditional essential genes may represent targets for the generation of attenuated vaccines, particularly in the case of bacterial conditional essential genes.

Furthermore, if a particular gene is essential or conditionally essential for a number of different bacteria, fungi, parasites, pests or plants, that gene and the polypeptide it encodes may represent a target for substances with a broad-spectrum  
10 of activity.

An essential or conditional essential gene identified by one of the methods described above using a transposon of the invention and the polypeptide which it encodes may be used in a method for identifying an inhibitor of transcription and/or translation of the gene and/or activity of the polypeptide encoded by the gene. Such  
15 a method may comprise identifying an essential or conditional essential gene using a method of the invention and then determining whether a test substance inhibits the transcription and/or translation of a gene thus identified or inhibits the activity of a polypeptide encoded by such a gene.

Such a substance may be referred to as an inhibitor of an essential or  
20 conditional essential gene. Thus, an inhibitor of an essential or conditional essential gene is a substance which inhibits expression and/or translation of that essential gene and/or activity of the polypeptide encoded by that essential or conditional essential gene.

Any suitable assay may be carried out to determine whether a test substance  
25 is an inhibitor of an essential or conditional essential gene. For example, the promoter of an essential or conditional essential gene may be linked to a coding sequence for a reporter polypeptide. Such a construct may be contacted with a test substance under conditions in which, in the absence of the test substance expression of the reporter polypeptide would occur. This would allow the effect of the test

substance on expression of the essential or conditional essential gene to be determined.

Substances which inhibit translation of an essential or conditional essential gene may be isolated, for example, by contacting the mRNA of the essential or conditional essential gene with a test substance under conditions that would permit translation of the mRNA in the absence of the test substance. This would allow the effect of the test substance on translation of the essential or conditional essential gene to be determined.

Substances which inhibit activity of a polypeptide encoded by the essential gene may be isolated, for example, by contacting the polypeptide with a substrate for the polypeptide and a test substance under conditions that would permit activity of the polypeptide in the absence of the test substance. This would allow the effect of the test substance on activity of the polypeptide encoded by the essential or conditional essential gene to be determined.

Suitable control experiments can be carried out. For example, a putative inhibitor should be tested for its activity against other promoters, mRNAs or polypeptides to discount the possibility that it is a general inhibitor of gene transcription, translation or polypeptide activity.

Suitable test products which can be tested in the above assays include combinatorial libraries, defined chemical entities, peptide and peptide mimetics, oligonucleotides and natural product libraries, such as display (e.g. phage display libraries) and antibody products. Antibody products include monoclonal and polyclonal antibodies, single chain antibodies, chimaeric antibodies and CDR-grafted antibodies.

Typically, organic molecules will be screened, preferably small organic molecules which have a molecular weight of from 50 to 2500 daltons. Candidate products can be biomolecules including, saccharides, fatty acids, steroids, purines, pyrimidines, derivatives, structural analogs or combinations thereof. Candidate agents are obtained from a wide variety of sources including libraries of synthetic or natural compounds. Known pharmacological agents may be subjected to directed or

random chemical modifications, such as acylation, alkylation, esterification, amidification, etc. to produce structural analogs.

Test substances may be used in an initial screen of, for example, for example from 10 to 100 substances per reaction, and the substances of these batches which show inhibition or stimulation tested individually. Test substances may be used at a concentration of from 1nM to 1000 $\mu$ M, preferably from 1 $\mu$ M to 100 $\mu$ M, more preferably from 1 $\mu$ M to 10 $\mu$ M. Suitable test substances for inhibitors of essential or conditional essential genes include combinatorial libraries, defined chemical entities, peptides and peptide mimetics, oligonucleotides and natural product libraries.

The test substances may be used in an initial screen of, for example, ten substances per reaction, and the substances of batches which show inhibition tested individually.

An inhibitor of an essential or conditional essential gene is one which inhibits expression and/or translation of that essential gene and/or activity of the polypeptide encoded by that essential or conditional gene. Preferred inhibitors of the invention are those which inhibit essential gene expression and/or translation and/or activity by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or at least 99% at a concentration of the inhibitor of 1 ngml<sup>-1</sup>, 10 ngml<sup>-1</sup>, 100 ngml<sup>-1</sup>, 500 ngml<sup>-1</sup>, 1  $\mu$ gml<sup>-1</sup>, 10  $\mu$ gml<sup>-1</sup>, 100  $\mu$ gml<sup>-1</sup>, 500  $\mu$ gml<sup>-1</sup>, 1 mgml<sup>-1</sup>, 10 mgml<sup>-1</sup>, 100mgml<sup>-1</sup>. The percentage inhibition represents the percentage decrease in expression and/or translation and/or activity in a comparison of assays in the presence and absence of the test substance. Any combination of the above mentioned degrees of percentage inhibition and concentration of inhibitor may be used to define an inhibitor of the invention, with greater inhibition at lower concentrations being preferred.

Test substances which show activity in assays such as those described above can be tested in *in vivo* systems, such as an animal model of infection for antibacterial activity or a plant model for herbicidal activity. Thus, candidate inhibitors could be tested for their ability to attenuate bacterial infections in mice in

the case of an antibacterial or for their ability to inhibit growth of plants in the case of a herbicide.

Inhibitors of bacterial, fungal or eukaryotic parasite essential or conditional essential genes may be used in a method of treatment of the human or animal body by therapy. In particular such substances may be used in a method of treatment of a bacterial, fungal or eukaryotic parasite infection. Such substances may also be used for the manufacture of a medicament for use in the treatment of a bacterial, fungal or eukaryotic parasite infections. The condition of a patient suffering from such an infection can be improved by administration of an inhibitor. A therapeutically effective amount of an inhibitor may be given to a human patient in need thereof. Inhibitors of bacterial, fungal or eukaryotic parasite essential or conditional essential genes may be administered in a variety of dosage forms. Thus, they can be administered orally, for example as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules. The inhibitors may also be administered parenterally, either subcutaneously, intravenously, intramuscularly, intrasternally, transdermally or by infusion techniques. The inhibitors may also be administered as suppositories. A physician will be able to determine the required route of administration for each particular patient.

The formulation of an inhibitor for use in preventing or treating a bacterial or fungal infection will depend upon factors such as the nature of the exact inhibitor, whether a pharmaceutical or veterinary use is intended, etc. An inhibitor may be formulated for simultaneous, separate or sequential use.

An inhibitor is typically formulated for administration in the present invention with a pharmaceutically acceptable carrier or diluent. The pharmaceutical carrier or diluent may be, for example, an isotonic solution. For example, solid oral forms may contain, together with the active compound, diluents, e.g. lactose, dextrose, saccharose, cellulose, corn starch or potato starch; lubricants, e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; binding agents; e.g. starches, gum arabic, gelatin, methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone; disaggregating agents, e.g. starch,

alginic acid, alginates or sodium starch glycolate; effervescing mixtures; dyestuffs; sweeteners; wetting agents, such as lecithin, polysorbates, laurylsulphates; and, in general, non-toxic and pharmacologically inactive substances used in pharmaceutical formulations. Such pharmaceutical preparations may be manufactured in known  
5 manner, for example, by means of mixing, granulating, tableting, sugar-coating, or film-coating processes.

Liquid dispersions for oral administration may be syrups, emulsions or suspensions. The syrups may contain as carriers, for example, saccharose or saccharose with glycerine and/or mannitol and/or sorbitol.

10 Suspensions and emulsions may contain as carrier, for example a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol. The suspensions or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol, and if desired,  
15 a suitable amount of lidocaine hydrochloride.

Solutions for intravenous administration or infusion may contain as carrier, for example, sterile water or preferably they may be in the form of sterile, aqueous, isotonic saline solutions.

A therapeutically effective amount of an inhibitor is administered to a patient.  
20 The dose of an inhibitor may be determined according to various parameters, especially according to the substance used; the age, weight and condition of the patient to be treated; the route of administration; and the required regimen. Again, a physician will be able to determine the required route of administration and dosage for any particular patient. A typical daily dose is from about 0.1 to 50 mg per kg of  
25 body weight, according to the activity of the specific inhibitor, the age, weight and conditions of the subject to be treated, the type and severity of the degeneration and the frequency and route of administration. Preferably, daily dosage levels are from 5 mg to 2 g.

Conditional essential genes are good candidates for use in the preparation of  
30 live attenuated vaccines. The principle behind vaccination is to induce an immune



response in the host thus providing protection against subsequent challenge with a pathogen. This may be achieved by inoculation with a live attenuated strain of the pathogen, i.e. a strain having reduced virulence such that it does not cause the disease caused by the virulent pathogen. Bacteria which carry mutations in conditional essential genes required for survival (i.e. growth/proliferation) in a host isolated according to the methods described above may be good candidates for use in live attenuated vaccines.

Mutations introduced into a bacterium for use in a vaccine generally knock-out the function of the conditional essential gene, for example a gene required for growth/proliferation in a host, completely. This may be achieved either by abolishing synthesis of any polypeptide at all from the gene or by making a mutation that results in synthesis of non-functional polypeptide. In order to abolish synthesis of polypeptide, either the entire gene or its 5'-end may be deleted. A deletion or insertion within the coding sequence of a gene may be used to create a gene that synthesises only non-functional polypeptide (e.g. polypeptide that contains only the N-terminal sequence of the wild-type protein).

The bacterium may have mutations in one or more, for example two, three or four conditional essential genes. The mutations are non-reverting mutations. These are mutations that show essentially no reversion back to the wild-type when the bacterium is used as a vaccine. Such mutations include insertions and deletions. Insertions and deletions are preferably large, typically at least 10 nucleotides in length, for example from 10 to 600 nucleotides. Preferably, the whole coding sequence is deleted.

The bacterium used in the vaccine preferably contains only defined mutations, i.e. mutations which are characterised. It is clearly undesirable to use a bacterium which has uncharacterised mutations in its genome as a vaccine because there would be a risk that the uncharacterised mutations may confer properties on the bacterium that cause undesirable side-effects.

The attenuating mutations may be introduced by methods well known to those skilled in the art. Appropriate methods include cloning the DNA sequence of

the wild-type gene into a vector, e.g. a plasmid, and inserting a selectable marker into the cloned DNA sequence or deleting a part of the DNA sequence, resulting in its inactivation. A deletion may be introduced by, for example, cutting the DNA sequence using restriction enzymes that cut at two points in or just outside the coding  
5 sequence and ligating together the two ends in the remaining sequence with an antibiotic resistance determinant. A plasmid carrying the inactivated DNA sequence can be transformed into the bacterium by known techniques such as electroporation or conjugation for example. It is then possible by suitable selection to identify a mutant wherein the inactivated DNA sequence has recombined into the chromosome  
10 of the bacterium and the wild-type DNA sequence has been rendered non-functional by homologous recombination.

The attenuated bacterium of the invention may be genetically engineered to express an antigen that is not expressed by the native bacterium (a "heterologous antigen"), so that the attenuated bacterium acts as a carrier of the heterologous  
15 antigen. The antigen may be from another organism, so that the vaccine provides protection against the other organism. A multivalent vaccine may be produced which not only provides immunity against the virulent parent of the attenuated bacterium but also provides immunity against the other organism. Furthermore, the attenuated bacterium may be engineered to express more than one heterologous antigen, in  
20 which case the heterologous antigens may be from the same or different organisms. The heterologous antigen may be a complete protein or a part of a protein containing an epitope. The antigen may be from a virus, prokaryote or a eukaryote, for example another bacterium, a yeast, a fungus or a eukaryotic parasite. The antigen may be from an extracellular or intracellular protein. More especially, the antigenic  
25 sequence may be from *E.coli*, tetanus, hepatitis A, B or C virus, human rhinovirus such as type 2 or type 14, herpes simplex virus, poliovirus type 2 or 3, foot-and-mouth disease virus, influenza virus, coxsackie virus or Chlamydia trachomatis. Useful antigens include non-toxic components of *E.coli* heat labile toxin, *E.coli* K88 antigens, ETEC colonization factor antigens, P.69 protein from  
30 *B.pertussis* and tetanus toxin fragment C.

The DNA encoding the heterologous antigen is expressed from a promoter that is active in vivo. Two promoters that have been shown to work well in *Salmonella* are the *nirB* promoter and the *htrA* promoter. For expression of the ET $\bar$ EC colonization factor antigens, the wild-type promoters could be used.

- 5 A DNA construct comprising the promoter operably linked to DNA encoding the heterologous antigen may be made and transformed into the attenuated bacterium using conventional techniques. Transformants containing the DNA construct may be selected, for example by screening for a selectable marker on the construct. Bacteria containing the construct may be grown in vitro before being formulated for
- 10 administration to the host for vaccination purposes.

- The vaccine may be formulated using known techniques for formulating attenuated bacterial vaccines. The vaccine is advantageously presented for oral administration, for example in a lyophilised encapsulated form. Such capsules may be provided with an enteric coating comprising, for example, Eudragate "S" (Trade
- 15 Mark), Eudragate "L" (Trade Mark), cellulose acetate, cellulose phthalate or hydroxypropylmethyl cellulose. These capsules may be used as such, or alternatively, the lyophilised material may be reconstituted prior to administration, e.g. as a suspension. Reconstitution is advantageously effected in a buffer at a suitable pH to ensure the viability of the bacteria. In order to protect the attenuated bacteria and the
- 20 vaccine from gastric acidity, a sodium bicarbonate preparation is advantageously administered before each administration of the vaccine. Alternatively, the vaccine may be prepared for parenteral administration, intranasal administration or intramuscular administration.

- The vaccine may be used in the vaccination of a mammalian host, particularly
- 25 a human host but also an animal host. An infection caused by a microorganism, especially a pathogen, may therefore be prevented by administering an effective dose of a vaccine prepared according to the invention. The dosage employed will ultimately be at the discretion of the physician, but will be dependent on various factors including the size and weight of the host and the type of vaccine formulated.

However, a dosage comprising the oral administration of from  $10^7$  to  $10^{11}$  bacteria per dose may be convenient for a 70 kg adult human host.

Inhibitors of bacterial, fungal and pest essential or conditional essential genes may be administered to plants in order to prevent or treat bacterial, fungal or pest  
5 infections; the term pest includes any animal which attacks a plant. Thus inhibitors of the invention may be useful as pesticides. Inhibitors of plant essential or conditional essential genes may be administered to plants in order to reduce or stop plant growth, that is to act as a herbicide.

The inhibitors of the present invention are normally applied in the form of  
10 compositions together with one or more agriculturally acceptable carriers or diluents and can be applied to the crop area or plant to be treated, simultaneously or in succession with further compounds.

The inhibitors of the invention can be selective herbicides, bacteriocides, fungicides or pesticides or mixtures of several of these preparations, if desired  
15 together with further carriers, surfactants or application-promoting adjuvants customarily employed in the art of formulation. Suitable carriers and diluents correspond to substances ordinarily employed in formulation technology, e.g. natural or regenerated mineral substances, solvents, dispersants, wetting agents, tackifiers, binders or fertilizers.

20 A preferred method of applying active ingredients of the present invention or an agrochemical composition which contains at least one of the active ingredients is leaf application. The number of applications and the rate of application depend on the intensity of infestation by the pathogen. However, the active ingredients can also penetrate the plant through the roots via the soil (systemic action) by impregnating  
25 the locus of the plant with a liquid composition, or by applying the compounds in solid form to the soil, e.g. in granular form (soil application). The active ingredients may also be applied to seeds (coating) by impregnating the seeds either with a liquid formulation containing active ingredients, or coating them with a solid formulation. In special cases, further types of application are also possible, for example, selective  
30 treatment of the plant stems or buds.

The active ingredients are used in unmodified form or, preferably, together with the adjuvants conventionally employed in the art of formulation, and are therefore formulated in known manner to emulsifiable concentrates, coatable pastes, directly sprayable or dilutable solutions, dilute emulsions, wettable powders, soluble  
5 powders, dusts, granulates, and also encapsulations, for example, in polymer substances. Like the nature of the compositions, the methods of application, such as spraying, atomizing, dusting, scattering or pouring, are chosen in accordance with the intended objectives and the prevailing circumstances. Advantageous rates of application are normally from 50g to 5kg of active ingredient (a.i.) per hectare ("ha",  
10 approximately 2.471 acres), preferably from 100g to 2kg a.i./ha, most preferably from 200g to 500g a.i./ha.

The formulations, compositions or preparations containing the active ingredients and, where appropriate, a solid or liquid adjuvant, are prepared in known manner, for example by homogeneously mixing and/or grinding active ingredients  
15 with extenders, for example solvents, solid carriers and, where appropriate, surface-active compounds (surfactants).

Suitable solvents include aromatic hydrocarbons, preferably the fractions having 8 to 12 carbon atoms, for example, xylene mixtures or substituted naphthalene, phthalate such as dibutyl phthalate or dioctyl phthalate, aliphatic  
20 hydrocarbons such as cyclohexane or paraffins, alcohols and glycols and their ethers and esters, such as ethanol, ethylene glycol, monomethyl or monoethyl ether, ketones such as cyclohexanone, strongly polar solvents such as N-methyl-2-pyrrolidone, dimethyl sulfoxide or dimethyl formamide, as well as epoxidized vegetable oils such as epoxidized coconut oil or soybean oil; or water.

25 The solid carriers used e.g. for dusts and dispersible powders, are normally natural mineral fillers such as calcite, talcum, kaolin, montmorillonite or attapulgite. In order to improve the physical properties it is also possible to add highly dispersed silicic acid or highly dispersed absorbent polymers. Suitable granulated adsorptive carriers are porous types, for example pumice, broken brick, sepiolite or bentonite;  
30 and suitable nonsorbent carriers are materials such as calcite or sand. In addition, a

great number of pregranulated materials of inorganic or organic nature can be used, e.g. especially dolomite or pulverized plant residues.

Depending on the nature of the active ingredient to be used in the formulation, suitable surface-active compounds are nonionic, cationic and/or anionic surfactants having good emulsifying, dispersing and wetting properties. The term "surfactants" will also be understood as comprising mixtures of surfactants. Suitable anionic surfactants can be both water-soluble soaps and water-soluble synthetic surface-active compounds.

Suitable soaps are the alkali metal salts, alkaline earth metal salts or unsubstituted or substituted ammonium salts of higher fatty acids (chains of 10 to 22 carbon atoms), for example the sodium or potassium salts of oleic or stearic acid, or of natural fatty acid mixtures which can be obtained for example from coconut oil or tallow oil. The fatty acid methyltaurin salts may also be used.

More frequently, however, so-called synthetic surfactants are used, especially fatty sulfonates, fatty sulfates, sulfonated benzimidazole derivatives or alkylarylsulfonates.

The fatty sulfonates or sulfates are usually in the form of alkali metal salts, alkaline earth metal salts or unsubstituted or substituted ammoniums salts and have a 8 to 22 carbon alkyl radical which also includes the alkyl moiety of alkyl radicals, for example, the sodium or calcium salt of lignonsulfonic acid, of dodecylsulfate or of a mixture of fatty alcohol sulfates obtained from natural fatty acids. These compounds also comprise the salts of sulfuric acid esters and sulfonic acids of fatty alcohol/ethylene oxide adducts. The sulfonated benzimidazole derivatives preferably contain 2 sulfonic acid groups and one fatty acid radical containing 8 to 22 carbon atoms. Examples of alkylarylsulfonates are the sodium, calcium or triethanolamine salts of dodecylbenzenesulfonic acid, dibutyl-naphthalenesulfonic acid, or of a naphthalenesulfonic acid/formaldehyde condensation product. Also suitable are corresponding phosphates, e.g. salts of the phosphoric acid ester of an adduct of p-nonylphenol with 4 to 14 moles of ethylene oxide.

Non-ionic surfactants are preferably polyglycol ether derivatives of aliphatic or cycloaliphatic alcohols, or saturated or unsaturated fatty acids and alkylphenols, said derivatives containing 3 to 30 glycol ether groups and 8 to 20 carbon atoms in the (aliphatic) hydrocarbon moiety and 6 to 18 carbon atoms in the alkyl moiety of the alkylphenols.

Further suitable non-ionic surfactants are the water-soluble adducts of polyethylene oxide with polypropylene glycol, ethylenediamine propylene glycol and alkylpolypropylene glycol containing 1 to 10 carbon atoms in the alkyl chain, which adducts contain 20 to 250 ethylene glycol ether groups and 10 to 100 propylene glycol ether groups. These compounds usually contain 1 to 5 ethylene glycol units per propylene glycol unit.

Representative examples of non-ionic surfactants are nonylphenolpolyethoxyethanols, castor oil polyglycol ethers, polypropylene/polyethylene oxide adducts, tributylphenoxypolyethoxyethanol, polyethylene glycol and octylphenoxyethoxyethanol. Fatty acid esters of polyoxyethylene sorbitan and polyoxyethylene sorbitan trioleate are also suitable non-ionic surfactants.

Cationic surfactants are preferably quaternary ammonium salts which have, as N-substituent, at least one  $C_8$ - $C_{22}$  alkyl radical and, as further substituents, lower unsubstituted or halogenated alkyl, benzyl or lower hydroxyalkyl radicals. The salts are preferably in the form of halides, methylsulfates or ethylsulfates, e.g. stearyltrimethylammonium chloride or benzyldi(2-chloroethyl)ethylammonium bromide.

The surfactants customarily employed in the art of formulation are described, for example, in "McCutcheon's Detergents and Emulsifiers Annual", MC Publishing Corp. Ringwood, New Jersey, 1979, and Sisely and Wood, "Encyclopaedia of Surface Active Agents," Chemical Publishing Co., Inc. New York, 1980.

The agrochemical compositions usually contain from about 0.1 to about 99% preferably about 0.1 to about 95%, and most preferably from about 3 to about 90% of the active ingredient, from about 1 to about 99.9%, preferably from about 1 to 99%,

and most preferably from about 5 to about 95% of a solid or liquid adjuvant, and from about 0 to about 25%, preferably about 0.1 to about 25%, and most preferably from about 0.1 to about 20% of a surfactant.

Whereas commercial products are preferably formulated as concentrates, the end user will normally employ dilute formulations.

The following Examples illustrate the invention:

### Examples

#### Materials and Methods

Unless indicated otherwise, the methods used are standard biochemical techniques. Examples of suitable general methodology textbooks include Sambrook *et al.*, Molecular Cloning, a Laboratory Manual (1989) and Ausubel *et al.*, Current Protocols in Molecular Biology (1995), John Wiley & Sons, Inc.

*E. coli* strains were grown on L-Agar (Sigma) and in L-Broth (Sigma). Kanamycin was purchased from Sigma. *S. typhimurium* SL1344 was grown in Tryptic Soy Broth (TSB, Oxoid).

#### Example 1. Construction of a Gene-Kelly transposon

The EZ:Tn R6k ori Kan transposon (Epicentre) was used as a PCR template with oligonucleotides:

97 (SEQ ID NO: 2)  
5'-CAGCTGTCCTTATACACATCTCCCTATAGTGAGTCGTATTACCCATAA  
TACCCATAATAGCTGTTTGCCAgtcgactctagg-3'; and  
98 (SEQ ID NO: 3)  
5'-CAGCTGTCCTTATACACATCTCTTCTATAGTGTCACCTAAATAGGGAT  
AACAGGGTAATGaattcgtaatacagatgt-3'.



ME are *italicised*, the RNA polymerase binding sites are in bold, and the homing endonuclease sites are underlined. These oligonucleotides incorporate the T7 RNA polymerase site with the homing endonuclease site *PI-PspI*, and the SP6 RNA polymerase site with the homing endonuclease site for *I-SceI*, respectively.

5 PCR was carried out according to protocol for Roche Expand Hi-fidelity Kit.

A first round of PCR, to introduce the homing endonuclease and RNA polymerase sites, was carried out with an initial denaturation step at 96°C for 3 min, then 5 cycles of 96°C 30s, 25°C 90s, 72°C 2min 30s, then a further 25 cycles at 96°C 30s, 50°C 90s, 72°C 2min 30s, final extension of 4 minutes and then cooled to 4°C.

10 The PCR product was separated by gel electrophoresis, and the band (corresponding to the expected product at 2044bp) cut out and Gel extracted according to the Qiagen gel extraction protocol. The PCR products were re-ligated (according to Gibco protocol for T4 DNA ligase) overnight at 16°C. The ligation mixture was then purified using the Qiagen Gel Extraction protocol and the circularised transposon  
15 eluted in 50 µl water. 1 µl of the Transposon DNA was then electroporated into 40 µl TransforMax™ EC100D™ *pir*<sup>+</sup> Electrocompetent *E. coli* (Epicentre; using 0.1 cm cuvettes at 200Ω, 25 µF and 20KV/cm), outgrowth was in 1 ml SOC medium (Gibco life technologies) for 1 h at 37°C. The transformation was then plated out on L-Agar (Sigma) plates containing Kanamycin at 30 µg/ml and incubated overnight at 37°C.

20 12 colonies were then picked and grown up overnight in LB-Kan 30 µg/ml and 1.5 ml of culture was used for DNA-mini-preps according to the Qiagen protocol. The DNA sequence of the resulting constructs was then determined on a Beckman CEQ DNA sequencer, (using manufacturers recommended conditions) with kan-2-FP-1 forward primer (Epicentre) as a DNA sequencing primer. The sequence of clone  
25 11(GK11) was found to contain a single base pair change in one of the ME sequences. To correct this sequence change, an experiment using a second round of PCR was designed with an oligonucleotide that corrected the single base pair change. The clone GK11 (harbouring a single-point mutation in the ME) was re-PCR'd using un-phosphorylated ME primers (96°C for 3min, followed by 30 cycles of 96°C for  
30 30s, 45°C for 90s, 72°C for 150s). The PCR products were then cloned into

pBAD-TOPO (Invitrogen) and transformed into *E. coli* TOP10 chemically competent cells according to the Invitrogen protocol. The transformation mix was plated out on L-Agar containing kanamycin at 30 µg/ml and incubated overnight at 37°C. 6 colonies were then picked and grown in L-Broth containing kanamycin at 30 µg/ml overnight at 37°C. DNA from 1.5 mL samples of these cultures was then prepared using the miniprep method (Qiagen QIAprep spin miniprep kit) according to the Qiagen protocol. The DNA sequences of the inserts from each of these 6 minipreps was then determined with oligonucleotides kan-2-FP-1 and R6kan-2-RP-1 (Epicentre) as sequencing primers according to Beckman CEQ protocol. One of the isolates, clone 6A was correct when sequenced, named pBAD-GK6A, and was selected for further study.

## **Example 2. Evaluation of the Gene-Kelly transposon**

### **(i) T7 and SP6 RNA polymerase evaluation**

In order to evaluate the novel transposon, 0.2 µg of pBAD-GK6A was used as template in an *in vitro* transcription (IVT) reactions using both SP6 (SP6 Megascript kit; Ambion) and T7 (T7 Megashortscript kit, Ambion) RNA polymerases, according to Ambion protocols. RNA produced was purified using the Qiagen RNeasy mini Kit, and the amount of RNA produced measured at A<sub>260</sub>. Transcription was observed both with the SP6 and T7 IVT reactions.

### **(ii) Restriction digest of transposon DNA with homing endonucleases**

In order to determine whether or not the homing endonuclease sites were functional in the GK transposon, plasmid DNA (0.5 µg) was digested with I-SceI and PI-PspI. Separation of the resulting DNA products by agarose gel electrophoresis showed a single linearised band of the correct size.

### **(iii) Transposition of *Salmonella typhimurium***

pBAD-GK6A (0.1 µg) was electroporated into 40 µl *S. typhimurium* SL1344 electrocompetent cells (SL1344 was grown to an OD 0.5 in 100 ml tryptic-soy broth

(TSB from Oxoid) at 37°C. Cells were centrifuged at 5000 x g for 10 min at 4°C, washed three times in 50 ml 10% glycerol before a final re-suspension in 1 ml of 10% glycerol) using a 0.2 cm cuvette, 200Ω, 25 μF and 12kV/cm, outgrowth was in 1 ml SOC (Gibco) at 37°C for 1 h, the transformation was then plated onto L-Agar plates containing Kanamycin at 50 μg/ml plates and grown overnight at 37°C. A colony was then picked and grown in 2.5 litres L-Broth containing Kanamycin at 50 μg/ml overnight at 37°C. A Qiagen Qiafilter Mega plasmid kit was used to purify pBAD-GK6A.

10 **Example 3. Generation of *S. typhimurium* SL1344 mutants with Transposon GK6a**

The transposome complex was generated from pBAD-GK6A as follows. pBAD-GK6a (100 μg) of was digested with *Xmn*I and *Nco*I (NEB) in NEB buffer 2 (with 1 μg BSA/ ml), overnight at 37°C. The entire digest was then run out on a 0.8% agarose gel, the ~2kb band, the GK transposon, was gel extracted using the Qiagen gel extraction kit, and eluted from 1 spin column in 50 μl TE pH8.5. The GK transposome complex was generated according to Epicentre protocols and electroporated into electrocompetent *S. typhimurium* SL1344 cells as described above. Following outgrowth the cells were subsequently plated out on Tryptic Soy Agar plates (TSA, Oxoid) containing Kanamycin at 50 μg/ml and incubated overnight at 37°C. A total of 480 mutants were picked and grown overnight in 2 ml TSB (Oxoid) containing Kanamycin at 50 μg/ml and glycerol stocks made (20% glycerol TSB).

25 **Example 4. Recovery of transposon for sequencing (use of R6k origin of replication)**

Transposons and adjacent flanking DNA, corresponding to genes that have been disrupted by transposon insertion can be recovered from mutant chromosomal DNA samples using the use of R6k origin of replication. Digestion of chromosomal DNA purified from *S. typhimurium* SL1344 GK mutants with a restriction enzyme

that does not cut in the transposon, followed by circularising the fragments, and transformation into a *pir*<sup>+</sup> strain of *E. coli*, results in the "rescuing" of this DNA.

Mutants 1-50 were grown up individually in 2 ml TSB containing Kanamycin at 50 µg/ml overnight at 37°C. Samples (1.5ml) was used to prepare chromosomal DNA using the Qiagen DNeasy tissue kit. A total of 5 µl (0.5 µg) of each of the fifty chromosomal preps was digested with *EcoRV* (NEB) in a final volume of 20 µl, overnight at 37°C. The *EcoRV* was heat inactivated at 80°C for 20 minutes. The 20 µl digest was then religated in 100 µl final volume using Gibco T4 DNA ligase, 48 hours at 4°C. Each religation was then individually cleaned up using a Qiagen gel extraction spin column and eluted in 50 µl water. Ligations (4 µl, 0.04 µg) were electroporated into electrocompetent *pir*<sup>+</sup> *E. coli* (EC100D, Epicentre) according to Epicentre protocols and plated on L-Agar containing Kanamycin at 30 µg/ml and incubated overnight at 37°C. Colonies were obtained from 46 of the electroporations, and were subsequently grown up in 5 ml L-Broth containing Kanamycin at 30 µg/ml 37°C overnight. Plasmid DNA (2 µg) from these clones was sequenced according to the Beckman CEQ protocol using oligonucleotide 108 as a sequencing primer (T7 end of the transposon).

#### Example 5. Generation of RNA run-offs using iPCR and IVT for target

##### 20 hybridisation to microarrays

The generation of labelled target from GK mutants can be achieved by inverse PCR (iPCR) amplification of each end of the transposon followed by IVT reactions using either SP6 or T7 RNA polymerises. A pool of 96 *S. typhimurium* SL1344 mutants was inoculated into L-Broth (10 ml) containing Kanamycin at 50 µg/ml and grown overnight at 37°C statically. Chromosomal DNA (20 µg) was prepared from 1.5ml of culture using the Qiagen DNeasy Kit, and 5 µl (0.5 µg) digested individually with the restriction enzymes *HaeIII*, *HhaI*, *Hpych4IV* and *RsaI* (NEB) in their respective NEB buffers in a final volume of 20 µl, overnight at 37°C. The enzymes were then heat denatured at 65°C for *HhaI*, *Hpych4 IV* and *RsaI* and 80°C for *HaeIII* for 20 min. Each 20 µl digest was then self-ligated with T4 DNA

ligase (Gibco) in a 100 µl reaction at 4°C for 48 h. Amplification of the DNA flanking each end of the transposon was achieved by iPCR. iPCR reactions to amplify the SP6 end of the transposon are performed with:

oligonucleotide 107 (SEQ ID NO: 4)

5'-CTACCCTGTGGAACACCTACATCT-3';

and one of either

oligonucleotide 115 (SEQ ID NO: 5)

5'-ATTACCTCTTTCTCCGCACCCGAC-3'; *RsaI* or *Hpych4IV* or

oligonucleotide 116 (SEQ ID NO: 6)

10 5'-CGACATAGATCCGGAACATAATGG-3'; *HaeIII* or *HhaI*,

depending on the restriction enzyme used (in brackets) to cut the chromosomal DNA.

iPCR reactions to amplify the T7 end of the transposon were performed with

oligonucleotide 108 (SEQ ID NO: 7)

5'-ACCTACAACAAAGCTCTCATCAACC-3'

15 and one of either

oligonucleotide 117 (SEQ ID NO: 8)

5'-ACAACCTATTAATTTCCCCTCGTC-3'; *RsaI*, *HaeIII* or *HhaI* or

oligonucleotide 118 (SEQ ID NO: 9)

5'-ATGTTGGAATTTAATCGCGGCCTC-3'; *Hpych4IV*,

20 depending on the restriction enzyme used (in brackets) to cut the chromosomal DNA.

iPCR reactions were then set up using Qiagen Taq polymerase according to the

Qiagen protocol. 4 µl (0.02 µg) of ligation was used as template for each iPCR

reaction. The reactions were initially denatured at 94°C 3' followed by 30 cycles of

94°C 30s, 65°C 90s, 72°C 90s followed by 7min extension at 72°C and then cooling

25 to 4°C. Each of the 8 iPCR's were purified using a Qiagen Gel extraction kit and the

DNA eluted in 5 µl water. Each iPCR product was then re-digested with its

respective restriction enzyme in a final volume of 50 µl (NEB) overnight 37°C. The

digests were then cleaned using a Qiagen Gel extraction kit (following the

manufacturers recommended procedure) and the DNA eluted in 50 µl EB pH8.5.

Each digested iPCR product (2 µl) was used as a template for both T7 and SP6 in vitro transcription reactions according to the Ambion protocol. The RNA was cleaned using the Qiagen Rneasy kit and eluted in 50 µl of RNase free water that was then placed in a UV transparent 96 well plate and the absorbance at 260 nm measured.

**Example 6. Ligation capture recovery of Gene Kelly transposon ends**

A significant advantage of the Gene Kelly (GK) transposon is that it permits the recovery of DNA fragments adjacent to the site of transposon insertion by a method that does not employ PCR, which is ligation capture. Essentially, because of the rarity of the I-SceI and PI-PspI homing endonuclease sites the T7 and SP6 promoter sites that are linked to these sites can be enriched from a pool of DNA by ligation of a biotinylated linker to the cut site followed by purification using Streptavidin linked magnetic beads. A ligation capture experiment was performed on pBAD-GK6A. Plasmid DNA (1 µg) was digested with PI-PspI overnight and the resulting linearised DNA purified using a Qiagen Gel extraction kit. This DNA (400 ng) was then digested overnight with HaeIII and subsequently dephosphorylated using Calf Intestinal Alkaline Phosphatase (Roche). Dephosphorylated DNA was then ligated overnight onto a biotinylated linker, generated by annealing oligonucleotide 113 (SEQ ID NO: 10)  
5'-biotin-GACGACCTCAGTTACGGTACGATCGGCCACGTAGCTTAT-3'  
and oligonucleotide 114 (SEQ ID NO: 11)  
5'-phosphate-GCTACGTGGCCGATCGTACCGTAACTGAGGTCGTC-3'.

The ligation was purified using a Qiagen Gel extraction. Biotinylated DNA was then extracted from the ligation using Streptavidin-linked magnetic particles (150 µg; Promega) according to the manufacturers protocol, and the beads finally resuspended in 8 µl of 1x HaeIII restriction buffer containing 10 units of HaeIII (NEB). The digestion was then incubated at 37°C for 2 hours to remove the T7 RNA promoter from the linker. The beads were removed and an IVT reaction performed on the supernatant using an Ambion T7 Megashortscript kit, according to the

manufacturers instructions. IVT products were purified using a Qiagen RNeasy kit, and the products eluted in 50 µl water and read at  $A_{260}$ .

From the sequence data obtained we were able to identify the transposon insertion point in the published *Salmonella* genome LT2. Figure 4 shows a graph showing the random distribution of the sites of GK transposon distribution in the LT2 genome for the 46 sequenced mutants.

**Example 7. Identification of genes in *Salmonella typhimurium* important for virulence in the mouse model of infection**

10. 480 random Gene Kelly transposon mutants were generated in *Salmonella typhimurium* SL1344. The mutants were grown individually in 1ml of L-broth in 96-well HTS plates, overnight and subsequently pooled. Chromosomal DNA (78.6µg) was purified and subsequently restriction digested separately with *Hae*III and *Rsa*I and the products purified with Qiagen gel extraction columns. The DNA was  
15 divided in half and separate IVT reactions (19.6µg DNA template/IVT) were performed with the respective RNA polymerase (SP6 and T7) resulting in the generation of labelled target (SP6 and T7 target was labelled with Cy5 and Cy3, respectively) corresponding to the DNA flanking both ends of transposon insertions.

DNA microarrays were designed based on the entire *Salmonella typhimurium*  
20 LT2 genome sequence, with probes synthesised in both the sense and anti-sense directions. Following hybridisation, the data were extracted from the arrays and analysed to identify those genes disrupted by transposon insertion within the pool of 480 mutants. New microarrays were designed incorporating probes corresponding to each site of transposon insertion.

25 The mutants were grown individually in 1ml of L-broth in 96-well HTS plates, overnight. Cultures were pooled ('Input pool') and chromosomal DNA purified from 50ml of the resultant culture ('Input pool' DNA). An inoculum of  $10^5$  cfu / ml PBS was generated from the 'input pool'. Mice were inoculated i.v. with  $10^5$  cfu of the 'input pool' and the infection allowed to proceed for 2.5 days, whereupon  
30 the mice were sacrificed and liver and spleen removed. Organs were pulverised in

10ml water and spread onto 4 x 120 mm diameter L-Agar plates and incubated overnight at 37°C. Bacteria ('output pool') were harvested from these plates by re-suspending the bacterial lawns in 10 ml L-broth / plate. Chromosomal DNA ('output pool DNA') was purified from 3 ml of this suspension.

- 5        'Input' and 'output pool' DNA (5µg) was digested overnight with the restriction endonuclease *RsaI*, and subsequently cleaned on a Qiagen Gel extraction column. *In vitro* transcription reactions were set up using the Ambion T7 and SP6 Megascript kits, using 2µg of digested DNA as template, with Cy3-CTP and Cy5-CTP, respectively, and incubated at 37°C for 24hrs. Following the DNaseI step RNA
- 10    was purified using a Qiagen nucleotide removal kit. The RNA from both the SP6 and T7 IVT reactions were then hybridised overnight to a DNA microarray containing probes corresponding to each transposon insertion site. Arrays were washed in 0.6xSSPE X followed by 0.06XSSPE 0.18%PEG200, each wash lasting 5min. Slides were then dried and analysed using an Agilent microarray scanner.
- 15    Several mutants in the pool of 96 were analysed using DNA sequencing to ascertain the precise point of transposition within the SL1344 chromosome. One mutant was characterised as containing a transposon within the *aroA* gene that would lead to the loss of its function. *AroA* mutants are one of the best genetically defined
- 20    *S. typhimurium* vaccine strains (Chatfield *et al.*, 1992; *Microb. Pathog.* 12: 145-151). These mutants are reduced in their ability to survive within susceptible mice compared to its wild type parent strain, such that 3 days post infection bacterial levels are reduced 1000-fold.

- 25    Data from the microarray images were extracted using Agilent's image analysis software and the data fed into a data viewing package. Array data from the input and output hybridisations were compared (see Figure 7).

- 30    Analysis of both the array image and the extracted data from the input pool reveal that target was generated to the *aroA* gene and that this target hybridised to the expected probes surrounding the site of transposon insertion. Analysis of the corresponding data from all three output pools revealed that significantly less target was hybridised to the probes corresponding to the *aroA* gene compared to two



control mutants with transposons disrupting other loci (gene X and an intergenic region) in the SL1344 genome. These data indicate that the *aroA* mutant is attenuated in its ability to survive within the mice. Therefore this technique allows the identification of genes that are important for the virulence of *S. typhimurium* in the mouse model of infection.

SEQUENCE LISTING

<110> ARROW THERAPEUTICS LIMITED

5 <120> TRANSPOSON

<130> P.84806A GCW

<160> 11

10 <170> PatentIn version 3.0

<210> 1

<211> 2044

15 <212> DNA

<213> Artificial transposon

<400> 1

	ctgtctctta	tacacatctc	ttctatagtg	tcacctaaat	agggataaca	gggtaatgaa	60
20	ttcgtaata	cagatgtagg	tggtccacag	ggtagccagc	agcatcctgc	gatgcagatc	120
	cggatgccat	ttcattacct	ctttctccgc	acccgacata	gatccgaaga	tcagcagttc	180
	aacctgttga	tagtacgtac	taagctctca	tgtttcacgt	actaagctct	catgtttaac	240
	gtactaagct	ctcatgttta	acgaactaaa	ccctcatggc	taacgtacta	agctctcatg	300
	gctaacgtac	taagctctca	tgtttcacgt	actaagctct	catgtttgaa	caataaaatt	360
25	aatataaatc	agcaacttaa	atagcctcta	agggttttaag	ttttataaga	aaaaaaagaa	420
	tatataaggc	ttttaagct	tttaagggtt	aacgggtgtg	gacaacaagc	cagggatctg	480
	ccatttcatt	acctctttct	ccgcaccga	catagatccg	gaacataatg	gtgcagggcg	540
	ctgacttccg	cgtttccaga	ctttacgaaa	cacggaaacc	gaagaccatt	catgttggtg	600
	ctcaggtcgc	agacgttttg	cagcagcagt	cgcttcacgt	tcgctcgcgt	atcggtgatt	660
30	cattctgcta	accagtaagg	caaccccgcc	agcctagccg	ggtcctcaac	gacaggagca	720
	cgatcatgcg	cacccggtgc	caggacccaa	cgctgcccga	gatgcgccgc	gtgcggctgc	780
	tggagatggc	ggacgcgatg	gatatgttct	gccaaagggt	ggtttgcgca	ttcacagggt	840
	gtctcaaaat	ctctgatgtt	acattgcaca	agataaaaat	atatcatcat	gaacaataaa	900
	actgtctgct	tacataaaca	gtaatacaag	gggtgttatg	agccatattc	aacgggaaac	960
35	gtcttgctcg	aggccgcgat	taaattccaa	catggatgct	gatttatatg	gggtataaatg	1020
	ggctcgcgat	aatgtcgggc	aatcaggtgc	gacaatctat	cgattgtatg	ggaagcccga	1080
	tgcgccagag	ttgtttctga	aacatggcaa	aggtagcggt	gccaatgatg	ttacagatga	1140
	gatggtcaga	ctaaactggc	tgacggaatt	tatgcctctt	ccgaccatca	agcattttat	1200
	ccgtactcct	gatgatgcat	ggttactcac	cactgcgac	cccggaaaaa	cagcattcca	1260
40	gggtattagaa	gaatatcctg	attcaggtga	aaatattggt	gatgcgctgg	cagtgttcct	1320
	gcgccggttg	cattcgattc	ctggttgtaa	ttgtcctttt	aacagcgatc	gcgtatttcg	1380
	tctcgctcag	gcgcaatcac	gaatgaataa	cggtttgggt	gatgcgagtg	attttgatga	1440
	cgagcgtaat	ggctggcctg	ttgaacaagt	ctggaaagaa	atgcataaac	ttttgccatt	1500
	ctcaccggat	tcagtcgtca	ctcatgggtga	tttctcactt	gataacctta	ttttgacga	1560
45	ggggaaatta	atagggttga	ttgatgttgg	acgagtcgga	atcgagacc	gataccagga	1620
	tcttgccatc	ctatggaact	gcctcgggtga	gttttctcct	tcattacaga	aacggctttt	1680
	tcaaaaatat	ggtattgata	atcctgatat	gaataaattg	cagtttcatt	tgatgctcga	1740
	tgagtttttc	taatcagaat	tggttaattg	gttgtaaac	tggcagagca	ttacgctgac	1800
	ttgacgggac	ggcggttttg	ttgaataaat	cgaacttttg	ctgagttgaa	ggatcagatc	1860
50	acgcattctc	ccgacaacgc	agaccgttcc	gtggcaaac	aaaagttcaa	aatcaccaac	1920
	tggtccacct	acaacaaagc	tctcatcaac	cgtggcgggg	atcctctaga	gtcgactggc	1980
	aaacagctat	tatgggtatt	atgggtaata	cgactcacta	tagggagatg	tgtataagag	2040
	acag						2044

<210> 2  
 <211> 85  
 <212> DNA  
 <213> Artificial oligonucleotide  
 5  
 <400> 2  
 cagctgtctc ttatacacat ctccctatag tgagtcgtat taccataat acccataata 60  
 gctgtttgcc agtcgactct agagg ..... 85  
 10  
 <210> 3  
 <211> 80  
 <212> DNA  
 <213> Artificial oligonucleotide  
 15  
 <400> 3  
 cagctgtctc ttatacacat ctcttctata gtgtcaccta aatagggata acagggtaat 60  
 ..... gaattcgta atacagatgt 80  
 20  
 <210> 4  
 <211> 24  
 <212> DNA  
 <213> Artificial oligonucleotide  
 25  
 <400> 4  
 ctaccctgtg gaacacctac atct 24  
 30  
 <210> 5  
 <211> 24  
 <212> DNA  
 <213> Artificial oligonucleotide  
 <400> 5  
 attacctctt tctccgcacc cgac 24  
 35  
 <210> 6  
 <211> 24  
 <212> DNA  
 <213> Artificial oligonucleotide  
 40  
 <400> 6  
 cgacatagat ccggaacata atgg 24  
 45  
 <210> 7  
 <211> 25  
 <212> DNA  
 <213> Artificial oligonucleotide  
 <400> 7  
 acctacaaca aagctctcat caacc 25  
 50

<210> 8  
<211> 24  
<212> DNA  
<213> Artificial oligonucleotide  
5  
<400> 8  
acaacctatt aatttcccct cgtc 24  
  
<210> 9  
10 <211> 24  
<212> DNA  
<213> Artificial oligonucleotide  
  
<400> 9  
15 atgttggaat ttaatcgcg cctc 24  
  
<210> 10  
-- <211> 39  
<212> DNA  
20 <213> Artificial oligonucleotide  
  
<400> 10  
gacgacctca gttacggtac gatcggccac gtagcttat 39  
  
<210> 11  
25 <211> 35  
<212> DNA  
<213> Artificial oligonucleotide  
  
<400> 11  
30 gctacgtggc cgatcggtacc gtaactgagg tcgte 35

CLAIMS

1. A transposon which comprises an RNA polymerase recognition site and a homing endonuclease recognition site.

5

2. A transposon according to claim 1 which comprises two RNA polymerase recognition sites.

3. A transposon according to claim 2, wherein the two RNA polymerase

10 recognition sites are diverse.

4. A transposon according to claim 3, wherein the two diverse RNA polymerase recognition sites are two of a T7 RNA polymerase recognition site, an SP6 RNA polymerase recognition site or a T3 RNA polymerase recognition site.

15

5. A transposon according to any one of the preceding claims which comprises two homing endonuclease recognition sites.

6. A transposon according to claim 5, wherein the two homing endonuclease

20 recognition sites are diverse.

7. A transposon according to claim 6, wherein the two diverse homing endonuclease recognition sites are an I-SceI recognition site and a PI-PspI recognition site.

25

8. A transposon according to any one of the preceding claims which further comprises a bacterial origin of replication.

9. A transposon according to any one of the preceding claims which is a

30 modified *Th5* transposon.

10. Use of a transposon according to any one of the preceding claims in a method for the identification of an essential or a conditional essential gene.
11. A method for identifying an essential gene of an organism, which method  
5 comprises:
- (i) providing a library of transposon insertion mutants of the said organism, wherein the transposon is a transposon according to any one of claims 1 to 10;
  - (ii) isolating chromosomal DNA from the library of (i);
  - 10 (iii) digesting the chromosomal DNA with a restriction endonuclease that is capable of cutting 5' to the RNA polymerase recognition site(s) in the transposon and 3' to the RNA polymerase recognition site(s) in the chromosomal DNA flanking the transposon insertion site;
  - (iv) transcribing the resulting digested DNA from the RNA polymerase  
15 recognition site(s) in the said DNA;
  - (v) hybridising the resulting RNA with an oligonucleotide array; and
  - (vi) identifying a probe on the oligonucleotide array which corresponds to an essential gene of the organism.
- 20 12. A method according to claim 11, wherein a labelled ribonucleotide is present when transcribing the digested DNA in step (iv).
13. A method according to claim 11, wherein step (v) is replaced by:
- (v)' reverse transcribing the resulting RNA; and
  - 25 (v)" hybridising the resulting cDNA with an oligonucleotide array.
14. A method according to claim 13, wherein a labelled deoxyribonucleotide is present when reverse transcribing the RNA in step (v)'.
- 30 15. A method according to claim 11 or 12, wherein:

- (a) the transposon is a transposon according to any one of claims 3 to 9;
- (b) step (iv) is carried out by transcribing one aliquot of the digested DNA with a first RNA polymerase and transcribing a second aliquot of the digested DNA with a second different RNA polymerase; and
- 5 (c) step (v) is carried out by hybridising the two resulting RNA pools with the same oligonucleotide array or separately with two copies of the same oligonucleotide array.

16. A method according to claim 15, wherein in step (b) the two aliquots of  
10 digested DNA are each transcribed in the presence of a different labelled ribonucleotide.

17. A method according to claim 13 or 14, wherein:

- (a) the transposon is a transposon according to any one of claims 3 to 9;
- 15 (b) step (iv) is carried out by transcribing one aliquot of the digested DNA with a first RNA polymerase and transcribing a second aliquot of the digested DNA with a second different RNA polymerase; and
- (c) step (v)" is carried out by hybridising the two resulting cDNA pools with the same oligonucleotide array or separately with two copies of the same  
20 oligonucleotide array.

18. A method according to claim 17, wherein the two aliquots of RNA resulting from step (b) are each reverse transcribed using a different labelled  
25 deoxyribonucleotide.

19. A method according to any one of claims 11 to 18, wherein:

- (a) aliquots of the chromosomal DNA are digested separately with different restriction endonucleases in step (iii);
- (b) each of the restriction endonucleases is capable of cutting 5' to the  
30 RNA polymerase recognition site(s) in the transposon and 3' to the RNA polymerase

recognition site(s) in the chromosomal DNA flanking the transposon insertion site;  
and

(c) each aliquot is subsequently treated separately in steps (iv) to (vi).

5 20. A method according to claim 19, wherein two or three aliquots of the  
chromosomal DNA are each digested separately with different restriction  
endonucleases.

21. A method according to any one of claims 11 to 20, wherein step (iii) is  
10 replaced by:

(iii)' digesting the chromosomal DNA with a homing endonuclease which  
is capable of cutting 5' to RNA polymerase recognition site(s) in the transposon;

(iii)" digesting the chromosomal DNA with a restriction endonuclease that  
is capable of cutting 3' to the RNA polymerase recognition site(s) in the

15 chromosomal DNA flanking the transposon insertion site; and

(iii)'" ligating the digested DNA with a biotinylated linker; and

(iii)'''' recovering the digested DNA using streptavidin-coated particles.

22. A method for identifying a conditional essential gene of an organism, which  
20 method comprises:

(a) providing a first sample of a library of transposon insertion mutants of  
the said organism (input library);

(b) providing a second sample of the library and subjecting that sample to  
a conditional restraint;

25 (c) collecting the mutants that survive the conditional restraint in step (ii)  
to give a second library (output library);

(d) carrying out a method according to steps (ii) to (iv) of any one of  
claims 11, 12, 15, 16 or 19 to 21 on the input library from step (a) and on the output  
library from step (c);

30 (e) hybridising the transcribed RNA derived from the input library and



from the output library separately to copies of the same oligonucleotide array or, if the RNA derived from the two libraries is differentially labelled, to the same oligonucleotide array; and

(f) identifying a probe on the oligonucleotide array(s) which corresponds to a conditional essential gene of the organism.

23. A method for identifying a conditional essential gene of an organism, which method comprises:

(a) providing a first sample of a library of transposon insertion mutants of the said organism (input library);

(b) providing a second sample of the library and subjecting that sample to a conditional restraint;

(c) collecting the mutants that survive the conditional restraint in step (ii) to give a second library (output library);

(d) carrying out a method according to steps (ii) to (v) of any one of claims 13, 14, 17, 18 or 19 to 21 on the input library from step (a) and on the output library from step (c);

(e) hybridising the reverse transcribed cDNA derived from the input library and from the output library separately to copies of the same oligonucleotide array or, if the cDNA derived from the two libraries is differentially labelled, to the same oligonucleotide array; and

(f) identifying a probe on the oligonucleotide array(s) which corresponds to a conditional essential gene of the organism.

24. A method according to claim 22 or 23, wherein the organism is a bacterium and the conditional restraint is growth of that bacterium in its host.

25. A method according to any one of claims 11 to 24, wherein the oligonucleotide array comprises probes which are from 9 to 150 bp in length and/or comprises 1 probe for every 60 to 250 bp of the locus or loci represented on the

array.

26. Use of an essential or conditional essential gene identified by a method according to any one of claims 11 to 25, or a polypeptide encoded by a said gene, in  
5 a method for identifying an inhibitor of transcription and/or translation of that gene and/or activity of a polypeptide encoded that gene.

27. A method for identifying an inhibitor of transcription and/or translation of an essential or conditional essential gene and/or an inhibitor of activity of a polypeptide  
10 encoded by a said gene, which method comprises:

(a) identifying an essential or conditional essential gene by a method according to any one of claims 11 to 25; and

(b) determining whether a test substance can inhibit transcription and/or translation of a gene identified in step (a) and/or activity of a polypeptide encoded by  
15 a said identified gene, thereby to identify a said inhibitor.

28. An inhibitor identified by a method according to claim 27.

29. An inhibitor according to claim 28 for use in a method of treatment of a  
20 bacterial, fungal or eukaryotic parasite infection, wherein the essential or conditional essential gene in claim 27 is a bacterial, fungal or eukaryotic parasite essential or conditional essential gene.

30. Use of an inhibitor according to claim 28 wherein the essential or conditional  
25 essential gene in claim 27 is a bacterial, fungal or eukaryotic parasite essential or conditional essential gene, in the manufacture of a medicament for use in the treatment of a bacterial, fungal or eukaryotic parasite infection.

31. A pharmaceutical composition comprising an inhibitor according to claim 28  
30 wherein the essential or conditional essential gene in claim 27 is a bacterial, fungal or

eukaryotic parasite essential or conditional essential gene and a pharmaceutically acceptable carrier or diluent.

32. A method of treating a host suffering from a bacterial, fungal or eukaryotic  
5 parasite infection, which method comprises the step of administering to the host a therapeutically effective amount of an inhibitor according to claim 28 wherein the essential or conditional essential gene in claim 27 is a bacterial, fungal or eukaryotic parasite essential or conditional essential gene.

10 33. A method for the preparation of a pharmaceutical composition, which method comprises:

(a) identifying an inhibitor of transcription and/or translation of an essential or conditional essential gene of an organism and/or an inhibitor of activity of a polypeptide encoded by a said gene by a method according to claim 27 wherein  
15 the essential or conditional essential gene is a bacterial, fungal or eukaryotic parasite essential or conditional essential gene; and

(b) formulating the inhibitor thus identified with a pharmaceutically acceptable carrier or diluent.

20 34. A method for treating a host suffering from a bacterial, fungal or eukaryotic parasite infection, which method comprises:

(a) identifying an inhibitor of transcription and/or translation of an essential or conditional essential gene of an organism and/or an inhibitor of activity of a polypeptide encoded by a said gene by a method according to claim 27 wherein  
25 the essential or conditional essential gene is a bacterial, fungal or eukaryotic parasite essential or conditional essential gene;

(b) formulating the inhibitor thus identified with a pharmaceutically acceptable carrier or diluent; and

(c) administering to the host a therapeutically effective amount of an  
30 inhibitor thus formulated.

35. An inhibitor according to claim 28, wherein the essential or conditional essential gene in claim 27 is a plant bacterial, plant fungal or plant pest essential or conditional essential gene.

5

36. Use of an inhibitor according to 35 as a plant bactericide, fungicide or pesticide.

37. An inhibitor according to claim 28, wherein essential or conditional essential  
10 gene in claim 27 is a plant essential or conditional essential gene.

38. Use of an inhibitor according to claim 47 as a herbicide.

39. A bacterium attenuated by a non-reverting mutation in one or more genes  
15 identified by a method according to any one of claims 22 to 25.

40. A vaccine comprising a bacterium according to claim 39 and a pharmaceutically acceptable carrier or diluent.

20 41. A bacterium according to claim 39 for use in a method of vaccinating a human or animal.

42. Use of a bacterium according to claim 39 for the manufacture of a medicament for vaccinating a human or animal.

25

43. A method for raising an immune response in a mammalian host, which method comprises the step of administering to the host a bacterium according to claim 39.

30 44. A method for preparing an attenuated bacterium, which method comprises:

(a) identifying a conditional essential gene in a bacterium by a method according to any one of claims 22 to 25; and

(b) introducing a non-reverting mutation into a thus-identified conditional essential gene of the bacterium, thereby to attenuate the bacterium.

5 45. A method for the preparation of a vaccine, which method comprises:

(a) identifying a conditional essential gene in a bacterium by a method according to any one of claims 22 to 25;

10 (b) introducing a non-reverting mutation into a thus-identified conditional essential gene of the bacterium, thereby to attenuate the bacterium; and

(c) formulating the attenuated bacterium with a pharmaceutically acceptable carrier or diluent.

15 46. A method for raising an immune response in a mammalian host, which method comprises:

(a) identifying a conditional essential gene in a bacterium by a method according to any one of claims 22 to 25;

(b) introducing a non-reverting mutation into a thus-identified conditional essential gene of the bacterium, thereby to attenuate the bacterium;

20 (c) formulating the attenuated bacterium with a pharmaceutically acceptable carrier or diluent; and

(d) administering to the host the attenuated bacterium thus formulated.

ABSTRACT

TRANSPOSON

- 5 A transposon which comprises an RNA polymerase recognition site and a homing endonuclease recognition site. The transposon may be used in methods for the identification of an essential gene or a conditional essential gene of an organism. Genes identified in such methods are useful as substrates for use in screening for antibacterials, antiparasitics, fungicides, pesticides and herbicides.




Fig. 1

CTGTCTCTTATACACATCTCTTCTATAGTGTACCTAAATAGGGATAACAGGG  
 TAATGAATTCGTTAATACAGATGTAGGTGTTCCACAGGGTAGCCAGCAGCATC  
 CTGCGATGCAGATCCGGATGCCATTTTATTAACTCTTTCTCCGCACCCGACATA  
 GATCCGAAGATCAGCAGTTCAACCTGTTGATAGTACGTACTAAGCTCTCATGT  
 TTCACGTACTAAGCTCTCATGTTTAAACGTACTAAGCTCTCATGTTTAAACGAAC  
 AAACCTCATGGCTAACGTACTAAGCTCTCATGGCTAACGTACTAAGCTCTCAT  
 GTTTCACGTACTAAGCTCTCATGTTTGAACAATAAAATTAATATAAATCAGCAA  
 CTAAATAGCCTCTAAGGTTTTAAAGTTTTATAAGAAAAAAGAATATATAAG  
 GCTTTTAAAGCTTTTAAAGGTTTTAACGGTTGTGGACAACAAGCCAGGGATCTGC  
 CATTTATTACCTCTTTCTCCGCACCCGACATAGATCCGGAACATAATGGTGCA  
 GGGCGCTGACTTCCGCGTTTCCAGACTTTACGAAACACGGAAACCGAAGACCA  
 TTCATGTTGTTGCTCAGGTGCGCAGACGTTTTGCAGCAGCAGTCGCTTACGTT  
 CGCTCGCGTATCGGTGATTCATTCTGCTAACAGTAAGGCAACCCCGCCAGCC  
 TAGCCGGGTCTCTAACGACAGGAGCAGCATCATGCGCACCCGTGGCCAGGAC  
 CCAACGCTGCCCGAGATGCGCCGCGTGCGGCTGCTGGAGATGGCGGACGCG  
 ATGGATATGTTCTGCCAAGGGTTGGTTTGCGCATTCACAGGGTGTCTCAAAAT  
 CTCTGATGTTACATTGCACAAGATAAAATATATCATCATGAACAATAAACTG  
 TCTGCTTACATAAACAGTAATACAAGGGGTGTTATGAGCCATATTCAACGGGA  
 AACGTTCTGCTCGAGGCCGCGATTAAATTCCAACATGGATGCTGATTTATATG  
 GGTATAAATGGGCTCGCGATAATGTGCGGGCAATCAGGTGCGACAATCTATCG  
 ATTGTATGGGAAGCCCGATGCGCCAGAGTTGTTTCTGAAACATGGCAAAGGT  
 AGCGTTGCCAATGATGTTACAGATGAGATGGTCAGACTAACTGGCTGACGG  
 AATTTATGCCTCTTCCGACCATCAAGCATTTTATCCGTACTCCTGATGATGCAT  
 GGTTACTCACCCTGCGATCCCCGGAAAAACAGCATTCAGGTATTAGAAGAA  
 TATCCTGATTCAGGTGAAAATATTGTTGATGCGCTGGCAGTGTTCTGCGCCG  
 GTTGCATTTCGATTCTGTTTGTAAATTGTCTTTTAAACAGCGATCGCGTATTTG  
 TCTCGCTCAGGCGCAATCACGAATGAATAACGGTTTGGTTGATGCGAGTGATT  
 TTGATGACGAGCGTAATGGCTGGCCTGTTGAACAAGTCTGGAAAGAAATGCA  
 TAACTTTTTGCCATTCTCACCGGATTCAGTCGTCACTCATGGTGATTCTCACT  
 TGATAACCTTATTTTTGACGAGGGGAAATTAATAGGTTGTATTGATGTGGAC  
 GAGTCGGAATCGCAGACCGATAACAGGATCTTGCCATCCTATGGAACCTGCCCT  
 GGTGAGTTTTCTCCTTCATTACAGAAACGGCTTTTTCAAAAATATGGTATTGAT  
 AATCCTGATATGAATAAATTGCAGTTTCAATTTGATGCTCGATGAGTTTTTCTAA  
 TCAGAATTGGTTAATTGGTTGTAACACTGGCAGAGCATTACGCTGACTTGACG  
 GGACGGCGGCTTTGTTGAATAAATCGAACTTTTGCTGAGTTGAAGGATCAGA  
 TCACGCATCTTCCCGACAACGCAGACCGTTCCGTGGCAAAGCAAAGTTCAA  
 ATCACCAACTGGTCCACCTACAACAAAGCTCTCATCAACCGTGGCGGGGATCC  
 TCTAGAGTCGACTGGCAAACAGCTATTATGGGTATTATGGGTAATACGACTCA  
 CTATAGGGAGATGTTGTATAAGAGACAG

Fig. 2






Fig. 3




Fig. 4




Fig. 5

6/7




Fig. 6




Fig. 7

20 MAR 2003

THE PATENT OFFICE  
20 MAR 2003  
Received in Patents  
International Unit

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**